Studies of the Nuclear Localization Signal and Pathway of E2 Protein of High Risk HPV 16 by Slavitskiy, Veniamin Ilich
Persistent link: http://hdl.handle.net/2345/bc-ir:103559
This work is posted on eScholarship@BC,
Boston College University Libraries.
Boston College Electronic Thesis or Dissertation, 2014
Copyright is held by the author, with all rights reserved, unless otherwise noted.
Studies of the Nuclear Localization
Signal and Pathway of E2 Protein of
High Risk HPV 16
Author: Veniamin Ilich Slavitskiy
Boston College 
Graduate School of Arts and Sciences 
Department of Biology 
 
 
 
 
 
 
 
 
STUDIES OF THE NUCLEAR LOCALIZATION 
SIGNAL AND PATHWAY OF E2 PROTEIN OF 
HIGH RISK HPV 16 
 
 
by  
 
VENIAMIN SLAVITSKIY 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the requirements  
for the degree of 
Doctor of Philosophy 
 
 
 
 
July 2014 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© copyright by VENIAMIN SLAVITSKIY 
2014  
 
 
Abstract 
Studies of the Nuclear Localization Signal and Pathway of E2 
Protein of High Risk HPV 16 
 
Veniamin Slavitskiy 
Thesis Advisor: Prof. Junona Moroianu, Ph.D. 
 
Human papillomaviruses (HPVs) are the most common sexually transmitted 
infection in the United States. High risk HPV types, including HPV 16, can cause 
cervical carcinomas upon infecting squamous basal epithelial cells. The HPV E2 
protein is a multifunctional protein that regulates viral DNA replication and 
expression of a large number of cellular and viral genes, including the E6 and E7 
viral oncogenes. 
Previous research in the Moroianu lab has identified a novel alpha-helical nuclear 
localization signal (NLS) in the C-terminal domain of HPV 16 E2 protein (75). 
Here, we focused on continuing the dissection of the HPV 16 E2 NLS and on 
identification of the nuclear import mechanism used by this protein. 
We identified several residues in the C-terminal domain of HPV 16 E2 
(327KHK329) and within the NLS (K299, C300) that enhance the function of the 
NLS. Additionally, we determined that dimerization of the C-terminal domain 
plays an important role in the nuclear import of HPV 16 E2 as a mutation that 
disrupted it led to a significant decrease in the nuclear localization of the protein. 
 
We discovered that importin 11 karyopherin is a nuclear import receptor for HPV 
16 E2. Our data suggest a nuclear import mechanism for HPV 16 E2 whereby 
UbcM2/UBE2E3 E2-type ubiquitin-conjugating enzyme acts as an adapter to 
bind HPV 16 E2 to importin 11 karyopherin for its nuclear import. This is a 
previously undescribed nuclear import mechanism which may have implications 
for the control of HPV 16 E2 functions. 
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Chapter 1 
Introduction 
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Human Papillomaviruses 
 
Papillomaviruses (PV) are small (around 60 nm in diameter), nonenveloped 
viruses with icosahedral capsid and double-stranded circular DNA genome that 
infect squamous basal epithelial cells causing a wide range of disease, including 
cancer (1-5). To date, more than 200 types of PVs have been identified 
(http://pave.niaid.nih.gov) of which the majority are human papillomaviruses 
(HPV). However the host range of PVs includes many species of mammals, birds 
and reptiles and it is likely that all amniotes harbor a variety of PV (6, 7). PVs are 
highly species-specific and cross-species infections are extremely rare (6, 8). It is 
believed that PVs evolve to occupy novel ecological niches within their host 
species, rather than adapt to a different host, therefore diversity within PVs 
infecting any one host species could be quite extensive (8).  
 
PVs are classified based on the sequences of their L1 gene and are divided into 
genera named after letters of Greek alphabet, from Alpha to Pi (10-12). HPVs are 
found within Alpha, Beta, Gamma, Mu and Nu genera (10-12) with the majority of 
them (90%) belonging to Alpha and Beta genera (1). Furthermore, based on their 
propensity to cause cancer, HPVs are classified into low risk or high risk types. 
The low risk types (e.g. HPV 6 and 11) cause mostly benign genital warts 
(condyloma acuminata), while the high risk types (e.g. HPV 16, 18, 31, 45) can 
induce the development of anogenital cancers, including cervical cancer, upon 
infection (1, 3, 15, 16). In particular, HPV 16 demonstrates viral fitness and rate 
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of persistence unmatched by other HPV types (50). It has been demonstrated 
that high risk HPV types produce fewer virions reducing the per-contact 
transmission rate but permitting longer infection (thus increasing the chance of a 
malignant outcome), whereas low risk HPV types produce large number of 
virions increasing the per-contact transmission rate but allowing for faster 
clearance by the immune system. The relative evolutionary advantage of each 
strategy depends on the sexual behaviors in a particular population (16). 
Interestingly, most PVs do not optimize their genetic code to align with the host 
species codon preferences. Since PVs rely on the host for translation, this may 
seem as a disadvantage, however, at least in the case of HPVs, the virus prefers 
to use the codons that are most likely to result in amino acid changes due to 
“unsafe” nucleotides in the wobble position. This could be regarded as an 
evolutionary mechanism constantly generating novel protein variants and 
expanding PVs diversity (7, 9). 
 
HPV infections have been causing disease since the ancient times. An HPV-
induced wart was found on the foot of the Egyptian mummy from 12 century BCE 
and in 400 BCE “Father of Medicine” Hippocrates described a way to treat penile 
warts using immune-stimulating herbs (13). In the early 20th century, Giuseppe 
Ciuffo demonstrated that the warts had viral origin by injecting himself with a cell-
free extract of a warty tissue. Later, in 1933, Richard Shope used extracts from 
papillomas in cottontail rabbits to show that the virus was species-specific and 
Peyton Rous could induce malignant transformation of the benign papillomas by 
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exposing them to chemical agents, thus demonstrating the possibility of HPV to 
cause cancer (13, 14).  
 
The PV genome is on average 8 kb in size and encodes 8 or 9 open reading 
frames (ORFs) (1). The viral transcripts are initiated at two major promoters, the 
early one that initiates upstream of E6 ORF and the late one that initiates 
transcription at several heterogeneous sites clustered around nucleotide 670 in 
HPV 16 and 742 in HPV 31 (1, 15). All known PVs encode at least five proteins:   
L1, L2, E1, E2 and E4. Additionally, many PVs, including the high-risk HPV 16 
and 18, encode E5, E6 and E7 proteins (8). The PV genomes do not encode 
polymerases or other enzymes necessary for viral replication and rely on the host 
cell’s machinery for DNA replication and protein synthesis (23). 
The viral capsid is composed of two proteins: 360 molecules of the major capsid 
protein L1 are organized into 72 pentameric capsomeres that form an 
icosahedral lattice. The core of the capsomeres is composed of a conserved 
antiparallel β-sandwich while the outwards facing loops are highly variable and 
determine the type specificity of a particular virus. One molecule of a minor 
capsid protein L2 is present at the center of each capsomere at the virion 
vertices (1, 2, 17, 18).  
 
The E1 is the most conserved protein among PVs (1, 15) and forms a complex 
with E2 protein at the origin of replication where E1 acts as a DNA helicase (1, 8, 
15, 19, 20). E2 also acts as a transcription factor regulating, among other genes, 
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the expression of E6 and E7 proteins (1, 8). Additionally, E2 is involved in viral 
DNA replication, genome maintenance and other functions (21). As E2 protein is 
the major focus of this work, it will be discussed in more detail in subsequent 
sections. 
 
The E4 protein is expressed by alternative splicing as a fusion with part of E1 to 
generate E1^E4 protein. Its role is thought to be in viral egress, regulation of 
gene expression via interaction with E4-DBD RNA helicase and cell cycle 
progression control where E1^E4 is able to induce a G2 arrest thus potentially 
counteracting the effects of E7 which functions to initiate progression to S phase 
(1, 15, 22). 
 
The E5 protein is thought to contribute to transforming activities of E6 and E7 
oncoproteins. E5 is a transmembrane protein that localizes primarily in the 
endoplasmic reticulum and the Golgi where it acts as a receptor for growth 
factors contributing to cell proliferation. Also, E5 may be involved in reducing the 
surface levels of major histocompatibility complex class I proteins leading to 
reduced immune response to viral infection (15, 23). The E6 and E7 
oncoproteins are the primary cause of high-risk HPVs transforming abilities and 
their functions will be discussed below in the context of HPV-induced cancer 
development. 
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PVs infect through microwounds that expose the basal epithelial layer (1, 15). 
Most PV types studied to date use heparan sulfate proteoglycans (HSPGs) as 
the primary attachment receptors (1, 2, 5, 15, 24, 32, 43). The surface-exposed 
basic residues of L1 mediate the attachment (2, 24). Following the attachment of 
the viral particle to the target cell’s surface, cyclophilin B, a chaperone protein, is 
thought to initiate a conformational change affecting L1 and L2 and leading to the 
exposure of the N-terminal end of L2 which seems to be required for successful 
internalization of the virus (2, 24). It has also been previously suggested that 
integrins α6 and α4β6 may play a role as PV cell surface receptors (1, 25). The 
viral endocytosis is thought to occur via tetraspanin-enriched microdomains 
(TEMs) for HPV 16 (2, 3), although previously clathrin and calveolin were 
implicated for this role (2-4, 33). It is possible that individual types of PV use 
different pathways for viral entry (2). Following their entry into the cell, PV virion 
particles disassemble in the late endosomes and lysosomes and the viral DNA is 
transferred to the nucleus by a mechanism involving the minor capsid protein L2 
(1, 2, 26-29). First viral transcripts can be detected about 12 hours post infection 
(1) and E1 and E2 proteins are expressed first followed by other Early genes (1, 
15, 21, 23). The action of E6 and E7 oncoproteins prevents the terminal 
differentiation of the basal epithelial cells (1, 15, 23, 25). Eventually, the infected 
cell moves up from the stratum basale into the suprabasal layer, the viral DNA is 
replicated in high copy number and the Late genes are expressed, resulting in 
the viral particle assembly and release (1, 15, 23, 25). 
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There is a rather strong association between HPV infection and cancer. Specific 
types of HPV (HPV 16, 18, 31, 33, 45, 51) are associated with over 95% of all 
cervical tumors and although the progression to cancer is relatively rare, cervical 
cancer is the third leading cancer killer of women worldwide (23, 34, 38, 42, 44). 
While in the United States the number of cervical cancer cases have declined by 
80% in the last 50 years due to Pap smear screening, worldwide almost 500,000 
new cases are diagnosed yearly (15). Moreover, immunocompromised 
populations, such as HIV-positive individuals, are at an increased risk for HPV 
infection and associated cancers (51). Large percentages of oropharyngeal, 
penile, vulvovaginal and anal cancers have been linked with HPV 16 and 18 as 
well (25, 44, 45). In addition, benign anogenital warts (condyloma acuminata) 
also present a significant medical problem and HPV infections make the most 
common sexually transmitted disease worldwide (46, 47, 48). Recently available 
vaccines target HPV 6, 11, 16 and 18, and are based upon L1-only virus-like 
particles (VLPs) (18, 43). A therapeutic vaccine based on HPV 16 and 18 E6 and 
E7 antigens is currently in clinical trials (133). Since it has been demonstrated 
that persistent HPV 16 infection results in toll-like receptors (TLRs) 
downregulation, TLR agonists, such as imiquimod, could be potentially used to 
treat HPV infections (49) and therapies based on making HPV infected cells 
sensitive to antiviral drugs via HPV E2-driven expression of herpes simplex virus 
thymidine kinase have been proposed (134). Additionally, in separate trials viral 
oncogenes E6 and E7 have been targeted with siRNA (135) and viral E1, E2, E6 
and E7 proteins have been targeted with small molecule inhibitors (136). 
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As mentioned above, during normal progression of HPV infection, viral E2 protein 
is expressed to regulate the expression of other Early genes, notably E6 and E7. 
This allows for precise control of viral DNA copy number. However, in some 
cases, recombination events lead to integration of E6 and E7 oncogenes into the 
host cell’s genome. Integration usually disrupts E2 gene leading to unregulated 
expression of E6 and E7. Moreover, the mRNAs expressed from integrated 
copied of oncogenes have increased stability and copy number which imparts a 
selective advantage to the cells with integrated oncogenes (23). The integration 
usually occurs in the vicinity of common fragile sites and may lead to disruption 
of important cellular genes, for example Notch1 (36, 109, 110). It should be noted 
that oncogenes integration is incompatible with the normal viral life cycle and 
confers no evolutionary advantage to the virus, therefore cancer must be 
considered an unfortunate side effect of the HPV infection (23, 34, 39, 42). 
The E7 oncoprotein has multiple binding targets in the host cell including 
Retinoblastoma protein (pRb), histone deacetylases (HDACs), p21 and p27 CDK 
inhibitors and cyclins. E6, in turn, targets p53 for degradation, activates 
telomerase expression and modulates the activities of PDZ domain-containing 
proteins and tumor necrosis factor receptors. Additionally, E6 and E7 induce 
genomic instability by inducing mitotic defects and then allowing the cells with 
abnormal centrosomes to proliferate via relaxation of G2-M checkpoint controls 
that are normally regulated by p53. E6 and E7 also induce DNA damage via the 
ATM-ATR pathway. Moreover, the HPV oncogenes target cytokine expression 
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and interferon response, contributing to immune evasion (1, 15, 23, 25, 34, 35, 
37-42, 45, 144). 
 
Nucleocytoplasmic Transport of Macromolecules 
 
Eukaryotes, unlike prokaryotes, possess a nucleus meaning that the 
chromosomes are surrounded by a double membrane called the nuclear 
envelope (NE). The NE allows for physical separation of DNA and RNA 
transcription, occurring within the nucleus, from protein synthesis taking place in 
the cytoplasm. Such separation is crucial to maintain precise control over 
numerous cell processes; however the cell must also have a way to transport 
proteins and RNAs across the NE. This transport is accomplished by large 
protein complexes called nuclear pore complexes (NPCs) that are essentially 
pores spanning the NE at the points where the two NE membranes join together 
to form trans-NE channels (52-56).  
 
Structurally, the NPC consists of about 30 different proteins known as 
nucleoporins (Nups) organized into an octogonally symmetrical cylinder. The 
NPC is a very large (60-125 MDa in vertebrates) structure of 400-600 protein 
molecules; however because of the 8-fold symmetry of the complex and because 
the proteins are present in multiple copies, only about 30 unique Nups are 
required. The structural Nups form the central core of the NPC. These proteins 
are organized into three rings (inner, outer and membrane rings) that form the 
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central channel. The NPC is anchored in the NE by the circular membrane of the 
nuclear pore passing between the membrane ring and the inner/outer rings and 
integral membrane proteins, termed Poms. The “FG Nups”, so named because 
of their phenylalanine-glycine repeats, attach to the inner face of the NPC core 
structure and form a mesh-like matrix providing attachment sites for the cargoes 
being transported by the NPC. On the cytoplasmic side of the complex, eight FG 
Nups provide points of attachment for cargoes, while on the nucleoplasmic side 
eight of their counterparts, linked by a distal ring, form a basket-like structure (52-
58). 
 
The central channel of the NPC has a diameter of about 30 nm which allows free 
passage of molecules of less than 40 kDa or 5 nm in diameter. Larger 
macromolecules overcome these limits my either interacting directly with the 
NPC Nups or by employing soluble transport factors. In this way, molecules up to 
39 nm in diameter can be translocated through the NPC (54). The most common 
group of transport factors is the evolutionary conserved karyopherin-β (Kapβ, 
importin/exportin) family. Karyopherins interact with their cargoes either directly 
or indirectly via adapter proteins, for example, karyopherin-β1/importin β interacts 
via karyopherin-α adapters (52-60).  
 
The proteins destined to be transported into or out of the nucleus possess 
targeting amino acid sequences: nuclear localization signal (NLS) for nuclear 
import or nuclear export signal (NES) for nuclear export. These sequences are 
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required and sufficient to target a protein into and out of the nucleus. To date, 
many types of NLSs have been identified. The first one to be characterized and 
one of the most frequent is the so-called “classical” monopartite NLS, a short 
stretch of basic amino acids (KKKRK, the NLS of SV40 T antigen). More complex 
classical “bipartite” NLSs consist of two basic clusters separated by a spacer of 
10-12 amino acids. While the cargoes containing classical NLS require the aid of 
karyopherin-α adaptor, most cargoes bind directly to importins. Many different 
NLSs have been identified, often containing positively charged amino acids. In 
many cases, the three-dimensional structure of the NLS is critical for its proper 
function. Kapβ proteins may assume a number of different conformations which 
allow them to bind and transport cargoes with different NLSs. In this way, a 
limited number of transport receptors are sufficient to transport thousands of 
dissimilar cargoes. Some cargoes require only one karyopherin whereas the 
concerted binding of several karyopherins is required for transport of other 
cargoes. Cargoes do not always use import receptors exclusively and some 
cargoes are able to utilize a pool of several karyopherins (52-61, 63-65). 
 
NESs are recognized by exportins. The best characterized nuclear export 
sequence is the hydrophobic leucine-rich NES that is recognized by exportin 
CRM-1. CRM-1 is able to transport proteins either by binding to them directly or 
with the help of adaptors containing NES. Other proteins rely on different 
exportins. In some cases, phosphorylation of the cargo protein is required for 
export, while in others phosphorylation inhibits nuclear export (55, 60). It is worth 
 12
noting that the “importin”/”exportin” terminology is somewhat vague as there are 
karyopherins that function in both nuclear import and export, although different 
cargoes are transported in each direction (54, 62). 
 
The major driving force for the transport of molecules across the NE is a small 
(25 kDa) GTPase Ran. In its GTP-bound form, RanGTP, it is able to interact with 
karyopherins and cycles across the NE. In the cytoplasm, RanGAP and RanBP1 
amplify the GTPase activity of Ran; in the nucleus, RanGEF (RCC1) acts as a 
nucleotide exchange factor, converting RanGDP to RanGTP. This results in a 
gradient of RanGTP across the NE which determines the directionality of the 
transport. Consequently, import complexes are formed in the cytoplasm where 
RanGTP concentration is low and dissociate in the nucleus where RanGTP 
concentration is high, whereas export complexes form in the nucleus in the 
presence of high concentration of RanGTP and dissociate in the cytoplasm 
following GTP hydrolysis by RanGAP (54, 55, 59, 60, 63, 64, 66). It should be 
mentioned that many Ran-independent import and export pathways exist (54, 55, 
67) and in addition to the Ran gradient, the nucleocytoplasmic transport is 
regulated in a variety of ways. This regulation includes inter- or intramolecular 
masking of the NLS/NES, amplification of the NLS/NES by phosphorylation, 
retention of a protein in a particular cellular compartment by association with 
another factor, transport in complex with other proteins and changes in 
availability of karyopherins or nucleoporins (54, 55, 60). 
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Nucleocytoplasmic Transport of Papillomavirus Proteins 
 
PVs depend on the host cell for their DNA replication and protein synthesis (23). 
Consequently, viral proteins and DNA have to enter and exit the nucleus (31). 
Similar to many other viral proteins (64), PV proteins have evolved to utilize the 
host cell’s protein transport machinery, as has been demonstrated by a large 
body of research, including work done in the Moroianu lab.  
 
L1 major capsid protein of HPV 11, 16 and 45 is imported by a classical pathway, 
using Kapα2β1 heterodimers as import receptors. L1 import is important during 
the productive phase of the infection when the L1 and L2 proteins are needed for 
capsid assembly. In addition to the classic import pathway, L1 of HPV 11 
interacts with Kapβ2 and Kapβ3 and inhibits the transport of these karyopherins 
into the nucleus (30, 31, 68-70). 
 
L2 minor capsid protein of HPV 11, 16, 18 and Bovine Papillomavirus (BPV) 1 
has two NLSs located at its positively charged termini. These NLSs may function 
independently and interact with Kapα2β1 heterodimer in a classic import pathway, 
as well as with Kapβ1, Kapβ2, Kapβ3 (HPV 11); Kapβ2 and Kapβ3 (HPV 16 and 
18). The L2 proteins of these HPV types may utilize multiple import strategies. In 
addition, HPV 16 L2 has an NES mediating its nuclear export and a nuclear 
retention sequence (NRS) that is essential during the initial phase of infection 
(26-29, 71). 
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E1 DNA helicase of HPV 11 contains a CRM-1 binding NES that is dominant 
over its NLS. The NES is controlled via phosphorylation by cyclin-dependent 
kinases (CDKs). Similar systems of control exist in HPV 31 and BPV1 E1 but 
different residues are phosphorylated. BPV1 E1 has been shown to be imported 
by Kaps α3, α4 and α5 (20, 72-74).  
 
E2 proteins contain different NLSs and NESs depending on the virus type and 
utilize various transport mechanisms (75-79, Chapter 3 of this thesis). As nuclear 
import of HPV 16 E2 protein is the topic of this research project, the relevant 
background information will be considered in detail in subsequent sections. 
E5 oncoprotein of HPV 16 has been shown to interact with karyopherin β3 (80), 
while E6 oncoprotein interacts with karyopherins β1 and β2 via its C-terminal 
NLS and also contains a classical NLS that interacts with Kapα2β1 heterodimer 
(81, 82). Additionally, a number of putative NLSs have been identified in HPV E6 
proteins using a computational biology approach (89). 
 
E7 oncoproteins of HPV 5, 8, 11 and 16 are imported via a Ran-dependent non-
classical pathway that involves a c-terminal NLS with a functionally required zinc 
finger motif. This NLS interacts directly with the FG repeats of Nup62 and 
Nup153. Also, HPV 11 and 16 E7 oncoproteins contain a leucine-rich NES within 
the zinc finger domain that mediates nuclear export via a CRM1-dependent 
pathway (83-88). 
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In summary, papillomavirus proteins have evolved a variety of different import 
and export pathways. As such, elucidation the exact mechanism of 
nucleocytoplasmic transport for a particular PV protein presents an interesting 
scientific challenge.  
 
HPV 16 E2 Protein and its Nucleocytoplasmic Transport 
 
The primary focus of this research project is to elucidate the nucleocytoplasmic 
transport strategies of the high-risk HPV 16 E2 protein. Consequently, the last 
section of this introduction reviews the existing body of research on HPV 16 E2’s 
structure, function and nucleocytoplasmic transport. 
 
HPV 16E2 structure 
 
E2 proteins have a molecular weight of about 50 kDa (15, 42, 90). They consist 
of two conserved domains, each with a distinct function: amino-terminal 
transactivation domain and carboxy-terminal DNA-binding domain. The domains 
are connected by a variable hinge (linker) region (21, 42, 75, 90-96, 103, 105).  
 
The structure of the N-terminal domain has been determined by X-ray 
crystallography for HPV 11, 16, 18 and BPV1. The transactivation domain forms 
a cashew-shaped structure where the N-terminal half of the domain is comprised 
of three long alpha helices folded into an anti-parallel bundle, whereas the C-
 16
terminal half of the domain contains anti-parallel beta sheets. These two regions 
are connected by a two-fold helix and the N-terminal alpha helix tightly packs 
against the beta sheet (21, 90, 94). Residues important for transactivation (Arg37, 
Ile73 in HPV 16) and replication (Glu39) are found on the outside, solvent-
exposed surfaces of the domain and are highly conserved (21, 90). The intact 
transactivation domains of HPV 16 E2 dimerize and the same residues that are 
essential for transactivation are also necessary for dimerization. It has been 
suggested that HPV 16 E2 N-terminal domains form “interdimers” by bringing 
together two already dimeric E2 molecules (formed via C-terminal domains, see 
below) bound to opposite sides of a DNA loop. This helps to stabilize the DNA 
loops and is essential for transactivation and replication (21, 90, 97). The N-
terminal domain dimerization occurs via different residues in BPV 1 E2 and is not 
strictly required for transactivation in that PV type (21, 98), while in HPV 11 and 
18, the N-terminal domain is monomeric (21). This variability may underscore 
important differences in transactivation and function between various PV types. 
 
The structure of the C-terminal DNA-binding domain has been determined by X-
ray crystallography and NMR spectroscopy for HPV 6, 16, 18, 31 and BPV 1 E2 
proteins. The domain’s structure is a dimeric eight-stranded anti-parallel beta 
barrel with two surface alpha helices making up the DNA recognition surface (Fig. 
1). The DNA binding site bends smoothly around the C-terminal domain to allow 
the interaction of the recognition helices with the major grooves of the DNA (21, 
91-93, 95, 96). Each monomer of the C-terminal domain is composed of two four-
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stranded anti-parallel beta sheets and two alpha helices found on one surface. 
Extensive hydrophobic interactions between the beta sheet and alpha helices 
stabilize the structure and these interactions are highly conserved between the 
E2 proteins of different PV types. The order of secondary structure elements is 
β1-α1-β2-β3-α2-β4; α1 is the recognition helix (91-93, 96). Although all known E2 
proteins bind to the same palindromic DNA sequence (ACCgNNNNcGGT) the 
amino acid composition of the “spacer” (NNNN) varies between PV types and 
determines the specificity of E2 proteins. Additionally, the 8-residue loop between 
β2 and β3 strands is disordered in HPV 16 E2 and it is not conserved, 
suggesting its function as another specificity determinant (91). Significant 
differences in DNA binding affinity exist between low and high risk HPV types 
and may determine the differences in transforming abilities of these viruses (91-
93, 96). 
 
Several residues are important in the formation of the E2 C-terminal domain 
dimer interface. These are hydrophobic residues, mostly Ile, His, Trp and Met. 
The most important residue is the highly conserved Trp360 in BPV 1 
(corresponding to Trp319 in HPV 16) that is called the “tryptophan bridge” and 
His288 in HPV 16 (conserved in HPV 18 and 33 but not in HPV 11 or BPV 1) (21, 
91-93, 99-102). Interestingly, the single chain mutants of HPV 16 E2 C-terminal 
domain show a 5-fold increase in the strength of binding to specific DNA sites, 
suggesting that the dimeric form evolved as a mean to precisely control E2 
binding to DNA needed for the protein’s functionality (104). 
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HPV 16 E2 Functions 
 
E2 is one of the five proteins encoded in the genomes of all known PVs (8). E2 
proteins have been established as the major transcriptional regulators of PVs. 
They can bind to specific sequences on the viral DNA and activate or repress 
transcription by recruiting cellular factors or by preventing the binding of cellular 
factors by steric hindrance, often achieved via short forms of E2 that compete 
with full length protein for DNA binding sites (21).  
 
Most importantly, E2 regulates the expression of E6 and E7 viral oncogenes via 
its transactivation domain and consequently suppresses the uncontrolled cell 
growth that may potentially lead to cancer (106, 107). Also, E2 is able to directly 
bind to E7 and thus inactivate the former protein by competing with E7’s natural 
targets (108). The loss of E2 gene that occurs when HPV genome is integrated 
into the host cell’s chromosome leads to uncontrolled expression of E6 and E7 
oncoproteins and the development of associated cancers (21, 35, 37).  
 
E2 directly binds to E1 helicase via E2’s N-terminal domain (111) and loads E1 
onto the viral origin of replication thus serving as an enhancer in the initiation of 
viral replication (21). A form of E2, called E8^E2C, where the N-terminal domain 
is replaced with a product of E8 viral gene, functions as a transcriptional 
repressor by competing with active form of E2 for DNA binding sites (21, 112).  
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The PV genome needs to be tethered to the host chromosomes in mitosis for 
retention, maintenance and partitioning. The E2 performs this tethering by 
binding to the viral DNA with its DNA-binding domain and to mitotic host 
chromosomes with its transactivation domain via protein adapters, the best 
studied of which is Brd4 protein (21). E2 proteins of HPV 16, 31, BPV 1 and other 
(but not all) PV types interact with Brd4 and form stable heterotetramers via the 
same residues that are involved in formation of N-terminal E2 dimers (21, 90, 
113, 114, 116). The interaction between E2 and Brd4 is enhanced by C-terminal 
dimerization of E2, thus making the formation of C-terminal dimers essential for 
E2 tethering function (115).  
 
E2 proteins are known to induce growth inhibition and apoptosis in host cells (21). 
The exact mechanism of this in HPV negative cells is unknown, however p53 
dependent pathways appear to be involved (21, 117, 118). Other mechanisms of 
E2 induced apoptosis may involve caspase 8 (118). In HPV positive cells (e.g. 
HeLa cells), E2 down-regulates E6 and E7 expression and, since HPV positive 
cells are dependent on the viral oncogenes expression for their sustained growth, 
expression of E2 leads to increased apoptosis (21, 106). This appears to happen 
via pRb and p21CIP dependent pathways (119). The rate of apoptosis in HeLa 
cells is increased from 6% to 20% following the expression of E2 in HeLa cells 
(117). 
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E2 is a rather short-lived protein, with half-life around 45-50 minutes (121, 122). It 
is degraded via a proteasome degradation pathway involving SCFSkp2 ubiquitin 
ligase at the end of G1 phase. The ubiquitination and degradation are preceded 
by phosphorylation at specific serine residues (298 and 301 in BPV 1) by casein 
kinase II (120, 121, 123, 124). The degradation occurs via interactions in the 
transactivation domain and deletion of this domain increases the proteins half-life 
more than 6-fold to 6 hours (121).  
 
The stabilization of E2 may happen via phosphorylation by Cdk2 in S phase of 
the cells cycle (122). Also, NRIP (nuclear receptor interaction protein) binds the 
transactivation domain of E2 and stabilizes it by recruiting calmodulin which 
activates the phosphatase calcineurin to dephosphorylate E2. Since Ca2+ acts as 
a regulator of keratinocyte differentiation, it stands to reason that Ca2+ levels are 
used to regulate E2 expression (125). 
 
E2 protein is generally viewed as a repressor of oncogenic transformation 
because it regulates the expression of E6 and E7 oncogenes and because E2 is 
generally lost in HPV-induced cancers. However, E2 proteins of high-risk HPVs 
have been shown to promote polyploidy, chromosomal mis-segregation and 
centrosome amplification leading to genomic instability. The interactions between 
high-risk E2 and activators of the anaphase promoting complex (APC), Cdc20 
and Cdh1, have been implicated in these processes (126). One hypothesis 
proposes that E2 brings the viral DNA close to the cellular DNA by binding to 
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both as described above and through E2-induced genomic instability and DNA 
breaks facilitates integration of viral DNA into the cellular genome. In this view, 
high-risk E2 could be considered an oncogene (127). In fact, E2 has been 
proposed as an early marker of viral infection as its expression has been 
detected in the cervical intraepithelial neoplasia (CIN), the stage preceding the 
invasive cervical carcinoma (128). 
 
Several studies have looked at interactions of E2 proteins with cellular molecules 
in order to elucidate how E2 might influence cellular physiology. The results 
indicate that E2 proteins act on a variety of cellular targets independently of E6 
and E7 viral oncoproteins. The cellular processes regulated by E2 include 
apoptosis, cell proliferation and differentiation, gene transcription, RNA 
processing, ubiquitination and degradation of proteins and intracellular transport. 
While E2 proteins of different PV types vary in their interaction networks, the end 
result is leading the cell towards a convenient environment for a replicative viral 
cycle (129-132). 
 
In summary, E2 is a versatile multifunctional protein that controls viral DNA 
replication and expression of a multitude of viral and cellular genes. The 
complete understanding of E2’s functions remains a scientific challenge for the 
future. 
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Nucleocytoplasmic Transport of HPV E2 
 
E2 proteins are synthesized outside of the nucleus and they need to be 
transported into the nucleus and, at least in some HPV types, out of the nucleus 
to bind targets in the cytoplasm. As described above, all E2 proteins share the 
general domain structure and significant sequence homology; however their 
nucleocytoplasmic transport mechanisms differ. 
 
BPV 1 E2 has two non-classic NLS sequences, one in the transactivation domain 
(107PKRCFKKGAV117) and the other in the DNA-binding domain 
(339KCYRFRVKKNHRHR352) (76). Partially conserved homologous sequences 
exist in other PV types (75) and in HPV 18 E2 a dominant NLS has been shown 
to be located in the C-terminal region (78). At the same time, HPV 18 E2 
contains a NES in its N-terminal domain that is absent in HPV 16 E2 (78).  
HPV 11 E2, in contrast, contains a classic monopartite NLS in its hinge region 
(236PPRKRARPG244) while the C-terminal NLS is much less conserved (75, 77).  
 
Previous research in the Moroianu lab has identified the NLS in the C-terminal 
domain of HPV 16 E2 as 298LKCLRYRFKKH308 (75). This NLS overlaps with the 
alpha helix involved in DNA binding (75, 91). This NLS is partially conserved in 
HPV 18 E2 (high risk HPV) but not in HPV 11 E2 (low risk HPV). No N-terminal 
NLS or NES exists in HPV 16 E2 (75). Therefore, it appears that differences exist 
between low and high-risk HPV E2 proteins in terms of their NLSs and moreover, 
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significant variability in the NLS types suggests that E2 proteins of different PV 
types use different karyopherins (75). 
 
It has been demonstrated that HPV 16 E2 is able to preferentially bind importin 
α5 in vitro, similar to BPV 1 E2, but HPV 11 E2 bound importin α3 and α5 with 
similar affinity, although these interactions have not been confirmed in vivo (79, 
129). No functional assay demonstrating the requirement for these importins has 
been performed and only five importins (α1, α3, α4, α5 and α7) have been tested 
for their binding to E2 proteins, leaving open the possibility that other importins 
may interact. 
 
The alpha-helical NLS of HPV 16 E2 is rather unusual; however Gag protein of 
Rous sarcoma virus (RSV) contains a similar alpha-helical NLS. Gag is imported 
by importin α and importin 11 karyopherins, with importin 11 binding to the alpha-
helical NLS in the MA domain, while importin α binds to the second NLS in NC 
domain to initiate import via a classical import pathway (137-139). 
 
This research project has continued the analysis of HPV 16 E2 NLS to identify 
additional residues important for NLS function. Several such residues were 
identified, including Trp319 residue previously known to be involved in 
dimerization of E2 C-terminal domain (100, 102). In the second part of my 
research project, I have demonstrated that importin 11 is required for the nuclear 
transport of HPV 16 E2 protein and that additionally, E2 appears to bind importin 
 24
11 via an adapter, UbcM2/UBE2E3, which has been previously known as a cargo 
of importin 11 (140). In summary, my research demonstrates that nuclear import 
of HPV 16 E2 protein occurs via a non-classical and previously undescribed 
pathway and several residues outside of the previously described NLS appear to 
be important for efficient import.  
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Chapter 2 
Materials and Methods 
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Plasmids and Mutagenesis 
 
EGFP-E2 and EGFP-cE2 plasmids were obtained previously (75). The following 
mutants were generated with QuickChange site-directed mutagenesis kit 
(Stratagene) using the mutagenesis primers shown below. The constructs were 
used to transform E. coli XL-1 Blue competent cells (Stratagene) per 
manufacturer’s protocol. The plasmids were purified using Quantum MidiPrep Kit 
(BioRad) per manufacturer’s protocol and verified by sequencing (Eurofins 
MWG). Plasmids were stored at -80°C in bacterial stock cultures supplemented 
with 15% glycerol. 
 
Mutagenesis primers (5’-3’): 
 
K299A 
Forward: 
GGTGATGCTAATACTTTAGCCTGTTTAAGATATAG 
Reverse:  
CTATATCTTAAACAGGCTAAAGTATTAGCATCACC 
C300A 
Forward: 
GGTGATGCTAATACTTTAAAAGCCTTAAGATATAG 
 Reverse: 
CTATATCTTAAAGCTTTTAAAGTATTAGCATCACC 
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327KHK/AAA329 
Forward: 
GGACAGGACATAATGTAGCCGCCGCCAGTGCAATTGTTACAC 
Reverse: 
GTGTAACAATTGCACTGGCGGCGGCTACATTATGTCCTGTCC 
W319G 
Forward: 
GCAGTGTCGTCTACAGGGCATTGGACAG 
Reverse:  
CTGTCCAATGCCCTGTAGACGACACTGC 
L301A 
Forward: 
GGTGATGCTAATACTTTAAAATGTGCGAGATATAGA 
Reverse:  
TCTATATCTCGCACATTTTAAAGTATTAGCATCACC 
F305A 
Forward: 
GTTTAAGATATAGAGCGAAAAAGCATTG 
Reverse: 
CAATGCTTTTTCGCTCTATATCTTAAAC 
V326STOP 
Forward: 
CGTCTACATGGCATTGGACAGGACATAATTGAAAACATAAAAGTGC 
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Reverse: 
GCACTTTTATGTTTTCAATTATGTCCTGTCCAATGCCATGTAGACG 
A331STOP 
Forward: 
GGACAGGACATAATGTAAAACATAAAAGTTGAATTGTTACAC 
Reverse: 
GTGTAACAATTCAACTTTTATGTTTTACATTATGTCCTGTCC 
 
Cell Culture 
 
HeLa cells (American Type Culture Collection, ATCC) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM; Sigma) supplemented with 10% 
heat inactivated fetal bovine serum (FBS; Sigma) and 1% penicillin/streptomycin 
(Sigma) in a 5% carbon dioxide environment at 37°C.  
 
Transient Transfections 
 
Analysis of Mutant Intracellular Localization Phenotypes 
 
HeLa cells were plated on 12 mm poly-L-lysine coated glass coverslips in 24-well 
plates and grown to approximately 60% confluency. The cells were transfected 
with 0.6 – 0.8 µg of EGFP plasmid construct using Fugene 6 transfection reagent 
(Roche) according to manufacturer’s protocol. Briefly, 4 µl of Fugene 6 were 
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mixed with the 0.6-0.8 µg of plasmid DNA in 97 µl of DMEM, incubated at room 
temperature for 20 minutes and added to the cells in 500 µl of DMEM (without 
supplements). The cells were incubated for 6 hours at 37°C in DMEM without 
supplements at which point the media was changed to DMEM supplemented with 
FBS and penicillin/streptomycin and the cells were incubated for additional 18 
hours. Following this, the cells were washed 3 times with phosphate buffered 
saline (PBS) on ice and fixed by incubating for 10 min in ice cold 3.7% 
paraformaldehyde (PFA) in PBS on ice followed by 3 washes with PBS on ice. 
The cells were mounted on glass microscope slides and stained with DAPI-
Vectashield (Vector Labs) to identify the nuclei. The cells were imaged using 
Leica TCS Sp5 broadband confocal microscope under 630X magnification using 
LAS AF software (Leica Microsystems) to obtain the images. The localization of 
the EGFP fusion proteins was analyzed using MetaMorph software (Molecular 
Devices) and the data were graphed using Prism 4 (GraphPad) and BoxPlotR 
software (141). 
 
Immunoblotting 
 
To ensure that the EGFP fusion proteins are intact and expressed at similar 
levels, the cells grown and transfected as above were solubilized with standard 
SDS-PAGE loading buffer and boiled for 10 minutes to lyse. The lysates were 
subjected to SDS-PAGE on a 12% polyacrylamide gel at 45 mA followed by a 
transfer to a nitrocellulose membrane at 75V for 45 minutes. The membrane was 
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stained with Ponceau stain to verify transfer, washed with dH2O and blocked in 
5% non-fat milk/0.1% Tween20 in PBS for 1 hour at room temperature on a 
rocker. The membrane was then incubated with a 1:1000 dilution of a primary 
mouse anti-EGFP antibody (Clontech) in blocking buffer for 1 hour at room 
temperature on a rocker, washed 3 times in the blocking buffer and incubated 
with a 1:1000 dilution of a secondary goat anti-mouse HRP-conjugated antibody 
(Santa Cruz Biotech) for 30 minutes at room temperature on a rocker, followed 
by 2 washes in the blocking buffer and 1 wash in PBS. The blots were developed 
using HyGLO Chemiluminescent HRP antibody detection reagent (Denville 
Scientific) per manufacturer’s protocol, exposed to HyBlot CL autoradiography 
film (Denvile Scientific) and detected on a Kodak X-Omat developer. 
 
Generation of HeLa Cell Lysates for Binding and Immunoprecipitation 
Experiments 
 
To obtain lysates of HeLa cells expressing EGFP fusion proteins for binding 
assay analysis, HeLa cells were grown in 75 cm2 flasks to ~60% confluency and 
transfected with 4-8 µg of plasmid DNA using 20 µl of Fugene 6 transfection 
reagent (Roche) mixed into 600 µl of DMEM, incubated for 20 minutes at room 
temperature and added to the cells in 10 ml of DMEM. Following a 6 hour 
incubation at 37°C, the media was changed to DMEM supplemented with FBS 
and penicillin/streptomycin and the cells were incubated for additional 18 hours. 
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The cells were collected by treating them with trypsin for 2 minutes at 37°C, 
washing with DMEM and centrifugation at 3000xG for 5 minutes. The cell pellets 
were washed in PBS and resuspended in 100 µl of lysis buffer (0.1% Triton X-
100 (Sigma), 5mM EDTA supplemented with protease inhibitors (0.05 mg/ml 
PMSF, 0.1 mg/ml leupeptin, 0.1 mg/ml aprotinin.) The cells were incubated under 
rotation for 30 minutes at 4°C and the cellular debris were collected by 
centrifugation at 13000 rpm in a microcentrifuge. The resulting extracts of soluble 
cellular components were stored at -80°C until needed.   
 
GST Fusion Proteins Purification 
 
GST-E2 and GST-cE2 plasmids were obtained previously (75). The plasmids 
were transformed into E. coli BL-21 CodonPlus cells (Agilent Technologies) per 
manufacturer’s protocol and the stock cultures were stored at -80°C in 15% 
glycerol. To purify the GST fusion proteins, the stock cultures were used to 
inoculate LB-ampicillin 10 ml starter culture overnight at 30°C. The starter culture 
was used to inoculate a 250 ml LB-ampicillin culture which was incubated at 
30°C until it reached OD600 of 0.6. GST protein expression was induced with 1 
mM IPTG for 2-3 hours at 30°C, bacterial cells were collected by centrifugation 
and the GST proteins were purified on glutathione-sepharose beads (GE 
Healthcare). Briefly, the bacterial cells were resuspended in 20-40 ml of lysis 
buffer (0.1 mg/ml lysozyme, 10% glycerol, 0.1 mg/ml aprotinin, 0.1 mg/ml 
leupeptin in PBS) and lysed by sonication using Branson sonifier 450. The 
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lysates were centrifuged for 60 minutes at 10500 x G to remove the insoluble 
debris. The cleared lysates were incubated with glutathione sepharose beads for 
60 minutes at 4°C under rotation. The beads were washed with wash buffer (1% 
glycerol in PBS) and the bound proteins were eluted with elution buffer (20 mM 
reduced glutathione, 0.1 mM EDTA, 100 mM Tris, pH 8, 1 mM MgCl2, 20 mM 
DTT, 10% glycerol) for 60 minutes at 4°C under rotation. The purified proteins 
were dialyzed into transport buffer (20 mM HEPES-KOH, pH 7.3, 110 mM 
potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 2 mM DDT, 
supplemented with protease inhibitors (aprotinin and leupeptin at 0.1 mg/ml). 
Protein purity and size were verified by SDS-PAGE and the purified proteins 
were stored at -80°C until needed.  
 
In vitro Nuclear Import Assay 
 
The nuclear import assays were performed essentially as previously described 
(70). Briefly, HeLa cells were grown to 60-70% confluency on poly-L-lysine 
coated glass coverslips in 24-well plates. The cells plasma membranes were 
permeabilized with 70 µg/µl digitonin for 5 minutes on ice and washed 3 times 
with cold transport buffer (described above) to remove the cytoplasmic 
components. The permeabilized cells were then incubated with import mixes 
containing an energy regenerating system (1 mM ATP, 1 mM GTP, 5 mM 
phosphocreatine, 0.4 U creatine phosphokinase), 10 µl HeLa cytosol extract 
(ATCC) and 0.25-0.5 µg of various GST fusion proteins. Additionally, antibodies 
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against various import receptors (karyopherins) were added to the import mixes 
as appropriate by the experimental design (1 mg per import mix). In several 
experiments, the HeLa cytosol was depleted of various import receptors by 
incubating it with 0.5 µg of antibody per 1 µl of cytosol for 1 hour at 4°C under 
rotation followed by incubation with 100 µl (50 µg) of protein A sepharose beads 
(Sigma) for 2 hours at 4°C under rotation and centrifugation for 2 minutes at 500 
rpm in the microcentrifuge to remove the beads. The depletion of karyopherins 
was verified by western blot. 
Following the incubation with the import mixes, the cells were fixed by incubating 
for 10 min in 3.7% paraformaldehyde (PFA) in PBS on ice and then the nuclear 
membranes were permeabilized by incubating in -20°C cold methanol for 3 
minutes at -20°C. In order to visualize the localization of GST fusion proteins, the 
fixed and methanol-permeabilized cells were blocked with 3% bovine serum 
albumin (BSA) in PBS for 1 hour at room temperature, followed by incubation 
with a 1:1000 dilution of anti-GST antibody (GE Healthcare) in 3% BSA for 1 hour 
at room temperature, 3 washes with 3% BSA in PBS and incubation with 1:100 
dilution of FITC conjugated rabbit anti-goat secondary antibody (Sigma) in 
3%BSA in PBS for 30 minutes at room temperature. The cells were then washed 
3 times with 3% BSA in PBS and 1 time with PBS. The cells were mounted onto 
microscope slides in DAPI-Vectashield (Vector labs) and allowed to dry. The 
images of the cells were taken on the Leica TCS Sp5 confocal microscope as 
described above or on the Nikon Eclipse TE300 microscope at 600x 
magnification. 
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In vitro Isolation Assay 
 
The GST fusion proteins were immobilized on glutathione sepharose beads by 
following the procedure for GST fusion proteins purification above, except the 
final elution step was omitted. The beads with immobilized proteins were 
equilibrated in transport buffer (described above). Fifty µl of beads with 
immobilized proteins were incubated with 1 ml of HeLa cytosol extracts (ATCC) 
with 0.1% Tween20 (Sigma) for 2 hours at 4°C under rotation. The beads were 
then washed 3 times with transport buffer and the bound proteins were eluted by 
boiling the beads in standard 2x SDS-PAGE loading buffer for 5 minutes. The 
elutions were analyzed by immunoblot using primary antibodies against 
karyopherins of interest and secondary antibodies conjugated to HRP. The 
presence of GST fusion proteins on the beads was verified by immunoblot with 
anti-GST antibody and also by SDS-PAGE followed by Coomassie blue staining. 
 
In vitro Immunoprecipitation 
 
HeLa cells were transfected with EGFP fusion plasmids, grown and lysed as 
described above but the lysis buffer volume was reduced to 30 µl to increase 
protein concentration and 1 mM GDP was added to the lysis buffer to stabilize 
the import complexes. The lysates were incubated with 20 µl (5 mg) of swollen 
protein A sepharose beads (Sigma) for 1 hour at 4°C under rotation to remove 
nonspecifically binding proteins. The beads were removed by centrifugation for 5 
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minutes at 13000 rpm in microcentrifuge. The cleared lysates were incubated 
with 2.5 µg of anti-EGFP antibody (Clontech) for 2 hours at 4°C under rotation. 
Following this, 20 µl (5 mg) of protein A sepharose beads were added and the 
incubation continued for an additional 1 hour. The beads with bound antibody-
protein complexes were collected by centrifugation at 500 rpm in the 
microcentrifuge for 3 minutes and washed 4 times with PBS. The bound proteins 
were eluted by boiling the beads in 10 µl of standard 4x SDS-PAGE loading 
buffer. The presence of putative EGFP-fusion protein-importin 11 binding was 
detected by immunoblot using the procedure described above; with anti-importin 
11 primary antibody (Novus) diluted 1:1000 and goat anti-rabbit-HRP secondary 
antibody (Santa Cruz Biotech) diluted 1:1000. Alternatively, the cleared lysates 
were incubated with 2.5 µg of anti-importin 11 antibody and the putative 
interaction was detected by immunoblot with anti-EGFP primary antibody 
(Clontech) diluted 1:2000 and goat anti-mouse-HRP secondary antibody (Santa 
Cruz Biotech) diluted 1:1000. 
 
HPV 16 E2 and Importin 11 Binding Assay 
 
GST fusion proteins (GST-E2, GST-UbcM2, GST) were purified as described 
above and either left bound to glutathione sepharose beads or eluted and then 
rebound to the beads at the ratio of 0.2 µg of protein per 1 µl of beads. The 
beads with bound GST fusion proteins were incubated with lysate of E. coli 
culture expressing induced 6His-importin 11 protein overnight at 4°C under 
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rotation. The beads were washed 3 times with wash buffer (1% glycerol in PBS) 
and the bound proteins were eluted by boiling the beads in standard 2x SDS-
PAGE loading buffer for 10 minutes. The presence of importin 11 in the elutions 
was detected with anti-importin 11 primary antibody (Life Span Biosciences) 
used at 1:250 dilution and goat anti-rabbit-HRP secondary antibody (Santa Cruz 
Biotech) used at 1:1000 dilution. The procedure for immunoblotting is described 
above. The pGex-UbcM2 and pET30-Importin 11 plasmids were kind gifts of Dr. 
Scott Plafker (Oklahoma Medical Research Foundation, OMRF) (140).  
 
HPV 16 E2 and UbcM2 Isolation Assay 
 
EGFP-E2 or EGFP-cE2 and EGFP-C1 (negative control) plasmids were 
transfected into HeLa cells for transient protein expression as described above. 
GST-UbcM2 and GST proteins were purified as described above and rebound to 
glutathione sepharose beads at the ratio of 0.2 µg of protein per 1 µl of beads. 
The HeLa cells lysates were prepared as described above and 50 µl of lysate 
was incubated with 40 µl of beads with bound GST fusion proteins overnight at 
4°C under rotation. The beads were collected by centrifugation at 500 rpm for 2 
minutes in microcentrifuge, washed 3 times with wash buffer (1% glycerol in 
PBS) and the bound proteins were eluted by boiling in standard 2x SDS-PAGE 
loading buffer for 10 minutes. The presence of bound EGFP fusion proteins was 
detected by primary anti-EGFP antibody (Clontech) diluted 1:5000 and a 
secondary goat anti-mouse-HRP antibody (Santa Cruz Biotech) diluted 1:1500. 
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Yeast Two-hybrid Binding Assay 
 
Yeast two-hybrid bait plasmids, pGBT10-importin 11 and pGBT10-importin 11 
(78-975) were kind gifts of Dr. Scott Plafker (OMRF). The yeast two-hybrid prey 
plasmid pACTII template was a kind gift of Dr. Charles Hoffman (Boston College).  
To generate pACTII-E2 and pACTII-cE2 plasmids, the appropriate fragments 
were created by PCR using pEGFP-E2 plasmid as a template and the following 
primers to amplify the E2 and cE2 gene sequences while introducing SmaI 
restriction site into the PCR products. 
Forward E2 primer: 
GATGTTCCAGATTACGCTAGCTTGGGTGGTCATATGGCCATGGAGACTCTTTGCCAAC
GTTTAAATG 
Forward cE2 primer: 
GATGTTCCAGATTACGCTAGCTTGGGTGGTCATATGGCCATGGAGACACCC
ATAGTACATTTAAAAGGTG 
Reverse primer: 
CACAGTTGAAGTGAACTTGCGGGGTTTTTCAGTATCTACGATTCATATAGAC
ATAAATCCAGTAGACAC 
The PCR reactions were set up using 6 ng of template plasmid DNA, 1.5 µg of 
forward and reverse primers, 50 mM MgSO4, 10 mM dNTP mix, 10X Pfx 
amplification buffer, 1 U of Pfx DNA polymerase in a final volume of 50 µl. The 
PCR reaction proceeded for 2 minutes at 94°C, 25 cycles of denaturation at 94°C 
for 30 seconds, annealing at 58°C for 30 seconds and extension at 68°C for 90 
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seconds, followed by a final extension at 68°C for 10 minutes. The PCR products 
were verified on a 1% agarose gel. 
The pACTII plasmid was digested with SmaI restriction enzyme (NEB) and 
transformed into Saccharomyces cerevisiae YRG2 competent cells along with 
either E2 or cE2 PCR products.  
To generate the competent yeast cells, an overnight culture of YRG2 cells grown 
at 30°C was diluted to 5x106 cells/ml and allowed to grow at 30°C until it reached 
107 cells/ml. The cells were pelleted for 5 minutes at 2000 rpm in a tabletop 
centrifuge and resuspended in 10 ml of sterile water, pelleted again and 
resuspended in 1 ml of sterile water and finally pelleted for 5 seconds and 
resuspended in 1x lithium acetate – TE buffer to wash, then pelleted and 
resuspended in 1x lithium acetate – TE at 2x109 cells/ml. 50 ul of competent cells 
were used per transformation reaction and mixed with 10 ng of digested pACTII 
plasmid and 5 µl of either E2 or cE2 PCR product. 50 µg of single stranded 
salmon sperm carrier DNA was added to each transformation reaction, the 
contents were mixed with 300 µl of lithium acetate – TE – PEG and incubated for 
3 hours at 30°C. Following this, 35µl of DMSO was added to each reaction, the 
reaction were mixed and heat-shocked in 42°C water bath for 15 minutes 
followed by incubation on ice for 10 minutes. The transformed cells were plated 
on SC medium lacking leucine (SC-leu) to allow selection for successful 
transformants and incubated at 30°C until colonies appeared (3 days). The 
colony PCR was performed on the resulting colonies to ensure the correct 
ligation of the insert into the plasmid. Fail Safe DNA polymerase (Epicentre) and 
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pACTII forward and reverse sequencing primers (IDT) were used for the colony 
PCR. Additionally, pACTII-E2 and pACTII-cE2 plasmids were purified using 
“Smash and Grab” protocol (142) and the plasmids were sequenced (Eurofins 
MWG).  
Either pGBT10-importin 11 of pGBT10-importin 11 (78-975) plasmids were 
transformed into the yeast cells containing pACTII-E2 or pACTII-cE2 plasmids 
using the protocol above, except the transformants were plated on SC medium 
lacking leucine and tryptophan (SC-leu-trp) to allow for selection of double 
transformants. Some transformants were patched to SC-leu plate and allowed to 
grow for 24 hours at 30°C. This plate was then replica plated onto SC-leu-trp-his 
(histidine) plates containing various concentration of 3-aminotriazol as well as to 
SC-leu-trp plates as positive controls and to use for filter lift β-galactosidase 
activity assay performed as described (143).  
 
 
 
 
 
 
 
 
 
 
 40
Chapter 3 
Investigation of the C-terminal NLS of HPV 16 E2 Protein 
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As mentioned in Chapter 1, previous research in the Moroianu lab has identified 
the NLS in the C-terminal domain of HPV 16 E2 (298LKCLRYRFKKH308) that 
overlaps with the alpha helix involved in DNA binding (75, 91). The original study 
that identified the NLS had established that RYR and KK sequences are required 
for nuclear import of HPV 16 E2 (75). However, other residues within the NLS 
were not analyzed in detail. Additionally, we hypothesized that several residues 
outside of the C-terminal NLS might be important for successful nuclear import 
based on either their similarity with established NLS sequences or their role in 
the maintenance of the protein’s quaternary structure (dimerization). Site directed 
mutagenesis was used to create several mutants, as shown in Fig. 1, and 
nuclear localization of these mutants was investigated by transient transfections 
in HeLa cells.  
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Figure 1: Schematic Overview of HPV16 E2 Protein 
 
The two domains are shown. The amino acid sequence of the DNA-binding 
domain is shown with the wild type sequence on top and mutant sequence on 
bottom. Individual mutants are differentiated by colors. The α-helical NLS is 
underlined. The position of α1 recognition helix is shown with the red box; the 
position of the disordered loop is shown with the blue box. The 3-dimentional 
diagram of the DNA-binding domain is shown in the bottom panel (diagram is 
adapted from Hegde and Androphy, J. Mol. Biol. (1998) 284, 1479.) 
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The Role of K299 and C300 in Nuclear Import of HPV 16 E2 
 
K299 and C300 residues are located at the N-terminal end of the HPV 16 E2 
NLS. Both lysine and cysteine residues have been known to be involved in the 
function of NLSs of HPV proteins (see Chapter 1). The role of K299 and C300 
has been investigated in the context of EGFP-16E2 and EGFP-16cE2 (residues 
286-365) fusion proteins. The representative images of transiently transfected 
HeLa cells are shown in Fig. 2, while the quantification of the results is presented 
in Fig. 5 and Table 1. The results show that while for the wild type EGFP-16E2, 
81% of the protein, as measured by EGFP signal, is localized to the nuclei. The 
K299A mutation reduces in the percentage of nuclear localization to 62.3%, a 
statistically significant decrease (as determined by two-tailed t-test). The C300A 
mutant shows a 73.4% nuclear localization, a very modest, yet also statistically 
significant decrease. In the case of EGFP-16cE2, the wild type protein shows an 
almost exclusively nuclear localization (92.7%), while for both K299A and C300A 
mutants, the percentage decreases by a very small amount (87.8% and 88.3%, 
respectively).  
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Figure 2: Effects of K299A and C300A Mutations on the 
Localization of EGFP-16E2 and EGFP-16cE2 
 
A. HeLa cells were transfected with either EGFP-16E2 wild type (panels A and E), 
EGFP-16E2 K299A (panels B and F), EGFP-16E2 C300A (panels C and G), or 
EGFP-C1 negative control (panels D and H) plasmids. 
 
B. HeLa cells were transfected with either EGFP-16cE2 wild type (panels A and 
E), EGFP-16cE2 K299A (panels B and F), EGFP-16cE2 C300A (panels C and 
G), or EGFP-C1 negative control (panels D and H) plasmids. 
 
All cells were examined by confocal fluorescence microscopy 24 hours post 
transfection. Panels A-D represent the fluorescence of EGFP, panels E-H 
represent the DAPI staining of the nuclei. 
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The Role of W319 in Nuclear Import of HPV 16 E2 
 
W319 residue is essential for the formation of the tryptophan bridge that is a 
critical element in the dimerization of the DNA-binding domains of HPV 16 E2 
protein (see Chapter 1). As such, W319G mutant was created in order to 
investigate the role of this important residue in nuclear import of HPV 16 E2. 
Glycine was chosen because it is non-hydrophobic and W360G mutation of the 
tryptophan bridge residue in BPV 1 resulted in the complete loss of dimerization 
(100). The representative images of HeLa cells transiently transfected with 
EGFP-16E2, EGFP-16cE2 or W319G mutants are shown in Fig. 3, while the 
quantitative data are presented in Fig. 5 and Table 1. The data show that the 
W319G mutation results in a very modest decrease in the nuclear localization of 
EGFP-16E2 (81% of the wild type protein localized to the nucleus vs. 73.3% for 
the mutant protein). However, in the context of EGFP-16cE2, the W319G 
mutation results in a significant shift from almost exclusively nuclear localization 
(92.7% nuclear) to pancellular localization (59.7% nuclear). It is worth noting that 
at 42 KDa the size of EGFP-16cE2 monomer is at the edge of the exclusion limit 
of the NPC, whereas EGFP at 32.7 KDa is well below the exclusion limit and, as 
such, is able to freely enter and exit the nucleus regardless of the presence of 
any NLS and NES. In this regard, it is important to notice that only 37.6% of 
EGFP negative control protein had nuclear localization, suggesting that EGFP-
16cE2 W319G monomeric proteins do not enter the nucleus by passive diffusion. 
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The Role of 327KHK329  Sequence in Nuclear Import of HPV 16 E2 
 
The 327KHK329 sequence is located 19 residues downstream of the C-terminal 
NLS of HPV 16 E2, outside of the DNA-binding alpha-helix (Fig. 1). Because 
HPV 16 E2 NLS, as well as several other known NLSs, contain critical lysine 
residues, we decided to investigate whether 327KHK329 had a role in the nuclear 
import of HPV 16 E2. Fig. 3 shows the representative images of HeLa cells 
transiently transfected with EGFP-16E2, EGFP16cE2 or KHK327AAA mutants 
and Fig. 5 and Table 1 show the quantitative data. In the context of both EGFP-
16E2 and EGFP-cE2, the 327KHK329 mutant displays a less nuclear localization 
that the wild type protein. For EGFP-E2, 57.6% of the mutant protein is nuclear 
vs. 81% for the wild type protein; for EGFP-cE2, 78.9% of the mutant protein is 
nuclear vs. 92.7% for the wild type protein. The p-values are similar in both cases 
(7.07 E-38 and 3.11 E-33 for EGFP-16E2 and EGFP-16cE2, respectively). These 
p-values indicate a statistically significant reduction in the nuclear localization of 
HPV-16 E2 protein resulting from mutating 327KHK329 sequence to AAA. 
 
In order to verify that all of the mutant proteins described above were properly 
expressed in HeLa cells, the cellular lysates of transiently transfected cells were 
investigated by immunoblot. The results demonstrated that all of the EGFP fusion 
proteins were properly expressed at similar concentrations and were not 
degraded (Fig. 4). 
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Figure 3: Effects of W319G and KHK327AAA Mutations on the 
Localization of EGFP-16E2 and EGFP-16cE2 
 
A. HeLa cells were transfected with either EGFP-16E2 wild type (panels A and E), 
EGFP-16E2 W319G (panels B and F), EGFP-16E2 KHK327AAA (panels C and 
G), or EGFP-C1 negative control (panels D and H) plasmids. 
 
B. HeLa cells were transfected with either EGFP-16cE2 wild type (panels A and 
E), EGFP-16cE2 W319G (panels B and F), EGFP-16cE2 KHK327AAA (panels C 
and G), or EGFP-C1 negative control (panels D and H) plasmids. 
 
All cells were examined by confocal fluorescence microscopy 24 hours post 
transfection. Panels A-D represent the fluorescence of EGFP, panels E-H 
represent the DAPI staining of the nuclei. 
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A                                                             B 
 
 
Figure 4: EGFP-16E2 and EGFP-16cE2 Mutant Proteins are 
Properly Expressed in HeLa Cells 
 
A. HeLa cells were transfected with EGFP-cE2 wild type (lane 1), EGFP-cE2 
C300A (lane 2), EGFP-cE2 K299A (lane 3), EGFP-cE2 KHK327AAA (lane 4), 
EGFP-cE2 W319G (lane 5), or EGFP-C1 plasmids (lane 6). Cell lysates were 
prepared 24 hours post transfection, subjected to Western blot and probed with 
anti-EGFP antibody. 
 
B. HeLa cells were transfected with EGFP-E2 wild type (lane 1), EGFP-E2 
C300A (lane 2), EGFP-E2 K299A (lane 3), EGFP-E2 KHK327AAA (lane 4), or 
EGFP-E2 W319G (lane 5) plasmids. Cell lysates were prepared 24 hours post 
transfection, subjected to Western blot and probed with anti-EGFP antibody. 
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In addition to the mutants described in this chapter, several other HPV 16 E2 
mutants were generated during the course of this research project which are 
described in Appendix A. 
 
To summarize, the work presented in this chapter continued the analysis of the 
previously identified C-terminal NLS of HPV 16 E2. We discovered that K299 and 
C300 residues contribute to the function of the NLS.  Additionally, several 
residues outside of the NLS (327KHK329 and W319) were analyzed and found to 
play a role in the nuclear import of HPV 16 E2. 
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Figure 5: Effects of Mutations on Cellular Distribution of EGFP-
16E2 and EGFP-16cE2 
 
The Y-axis shows the percentage of EGFP fusion protein that is localized to the 
cell nucleus as determined by MetaMorph software. The data represent a 
cumulative average of 10 independent transfections (at least 100 individual cells) 
graphed as a Box plot with Tukey-defined whiskers using BoxPlot software. 
Boxes represent the interquartile range (IQR), or the middle 50% of the data 
values. The whiskers extend to the data values that are less than 1.5 IQR. The 
circles represent outlier data points. The solid horizontal bars represent the 
median values. 
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Table 1: Statistical Data on the Effects of Mutations on Cellular 
Distribution of EGFP-16E2 and EGFP-16cE2 
 WT CA KA KHK WG cWT cCA cKA cKHK cWG C1  
Mean 
(%) 
81.06 73.41 62.32 57.62 73.34 92.75 88.38 87.85 78.90 59.77 37.61 
P value  n/a 2.10 
E-04 
3.26 
E-19 
7.07 
E-38 
1.06 
E-05 
n/a 2.83 
E-04 
3.16 
E-05 
3.11 
E-33 
1.08 
E-89 
5.9 
E-126*  
Number 
of Cells 
173 102 108 144 109 302 148 156 153 109 203 
The mean values represent the percentage of EGFP fusion protein that is 
localized to the nucleus as determined by MetaMorph software. The P value 
measures significance of the data, as determined by two-tailed t-test, compared 
to wild type protein (either WT or cWT); smaller values represent more 
statistically significant change.  
(*) The P value for EGFP-C1 negative control is shown vs. EGFP-16E2 (WT); the 
P value vs. EGFP-16cE2 (cWT) is 1.50 E-242. 
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Chapter 4 
Investigation of the Role of Importin 11 in the Nuclear Import of 
HPV 16 E2 Protein 
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As stated in Chapter 1, the nuclear import of E2 protein of high risk HPV 16 is 
dependent upon a NLS (298LKCLRYRFKKH308) in the DNA binding (C-terminal) 
domain of the protein. This NLS is only partially conserved in high risk HPV 18 
(LKCLRYRLRKH) and not conserved in low risk HPV 11 (LKCFRYRLNDK) (75). 
Unlike the classical NLS, which binds karyopherins in an extended conformation 
and therefore is not dependent on the secondary structure elements for its 
function, the 16E2 NLS overlaps with the DNA binding alpha helix (75, 91). 
Literature analysis before the beginning of this research project revealed that MA 
domain of Gag protein of Rous sarcoma virus (RSV) contained an alpha-helical 
NLS that was similar in structure to the C-terminal NLS of HPV16 E2 (137). The 
MA domain of Gag was found to be imported in Saccharomyces cerevisiae with 
the aid of Kap120 karyopherin, which is homologous to importin 11 in humans, 
and in avian cells via mammalian importin 11 (137, 138). Based on this, we 
hypothesized that importin 11 is the most likely candidate for the role of the 
import receptor of HPV 16 E2.  
 
Nuclear Import Assays Demonstrate that Importin 11 is Required for the Nuclear 
Import of HPV 16 E2 
 
To analyze the importance of importin 11 for nuclear import of HPV 16 E2, anti-
importin 11 antibody was used to block importin 11 during an import assay. As 
shown in Fig. 6, when anti-importin 11 antibody was added to the import mix, 
localization of GST-16cE2 changed from nuclear to cytoplasmic (panels B and C). 
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Adding anti-Kapβ2 antibody had no effect on the localization of GST-16cE2 
(panel D). On the other hand, addition of anti-Kapβ2 to the import mix changed 
the localization of M9-GST from nuclear to cytoplasmic (panels F and H), 
whereas anti-importin 11 antibody had no such effect (panel G). GST localized to 
cytoplasm regardless of the presence of HeLa cytosol extracts, energy mix or 
antibodies. This experiment demonstrates that importin 11 is required for nuclear 
import of HPV 16 E2 protein and that the requirement is specific as blocking a 
different karyopherin had no effect on GST-16cE2 localization. The nuclear 
import of M9-GST control was inhibited in the presence of anti-Kapβ2 antibody 
which specifically blocked the karyopherin known to import the M9 NLS.  
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Figure 6: Nuclear Import of GST-16cE2 is Inhibited in the 
Presence of Anti-importin 11 Antibody 
 
Digitonin-permeabilized HeLa cells were incubated with either GST-16cE2 
(panels A-D), M9-GST (panels E-H), or GST (panels I-L) in the presence of 
transport buffer (TB, panels A, E, I), HeLa cytosol and energy mix (HC, panels B, 
F, J), HeLa cytosol, energy mix and anti-importin 11 antibody (panels C, G, K), or 
HeLa cytosol, energy mix and anti-Kapβ2 antibody (panels D, H, L). Following 
the incubation, cells were fixed with paraformaldehyde and the localization of 
GST fusion proteins was detected with anti-GST primary antibody and FITC-
conjugated secondary antibody and examined by confocal fluorescence 
microscopy. 
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To confirm the observations made in the previous experiment, anti-importin 11 
antibody was used in combination with protein A sepharose to deplete HeLa 
cytosol extracts of importin 11. Protein A sepharose binds IgGs, and therefore is 
able to precipitate any antibody bound protein out of solution. As can be seen in 
Fig. 7A, importin 11 was successfully depleted from HeLa cytosol. This depleted 
cytosol was then used in a nuclear import assay to test whether the absence of 
importin 11 had an effect on the nuclear localization of E2. As Fig. 7B shows, 
immunodepletion of importin 11 resulted in the change of localization of GST-
16cE2 from nuclear to cytoplasmic, similar to negative control where only 
transport buffer was used (compare panels A, B and C). At the same time, 
nuclear localization of M9-GST, which uses karyopherin β2 as an import receptor 
(145), was unaffected by immunodepletion of importin 11 (panels D, E and F). 
GST was used as a negative control and localized in the cytoplasm regardless of 
the presence or absence of karyopherins or energy mix demonstrating that NLS 
is required for a successful nuclear import (panels G and H). The results of this 
experiment are in agreement with the nuclear import assay presented in Fig. 6 
and demonstrate that the presence of importin 11 is required for HPV 16 E2 to 
localize in the nucleus. 
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Figure 7: Depletion of HeLa Cytosol of Importin 11 Inhibits 
Nuclear Import of GST-16cE2  
 
A. HeLa cytosol used in the import assay is depleted of importin 11 following the 
incubation with anti-importin 11 antibody and protein A sepharose (left lane, (--)). 
Importin 11 is present in the HeLa cytosol used for positive control (right lane, 
(+)). Anti-importin11 antibody was used for detection. IPO11, importin 11; PA, 
protein A. 
 
B. Digitonin-permeabilized HeLa cells were incubated with either GST-16cE2 
(panels A-C), M9-GST (panels D-F), or GST (panels G and H) in the presence of 
transport buffer (TB, panels A, D, G), HeLa cytosol and energy mix (HC, panels 
B, E, H), or HeLa cytosol depleted of importin 11 (panels C and F). Following the 
incubation, cells were fixed with paraformaldehyde and the localization of GST 
fusion proteins was detected with anti-GST primary antibody and FITC-
conjugated secondary antibody and examined by fluorescence microscopy. 
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In order to confirm that the proteins used in nuclear import assays were properly 
expressed and purified, SDS-PAGE and Coomassie staining were used (Fig. 8). 
The results showed that GST-16cE2, M9-GST and GST used in nuclear import 
assays were pure and present at relatively similar concentrations. 
 
In summary, nuclear import assays indicated that importin 11 was required for 
nuclear localization of GST-16cE2 protein. This observation led to analysis of 
binding of E2 protein to importin 11 since many known NLSs directly interact with 
karyopherins. 
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Figure 8: Proteins Used in Nuclear Import Assays are Properly 
Expressed and Purified 
 
Proteins expressed in BL-21 CodonPlus cells, GST-16cE2 (lane 1), M9-GST 
(lane 2), and GST (lane 3), were purified, run on a 12% SDS-PAGE gel and 
visualized by Coomassie Brilliant blue staining. 
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Isolation Assays to Test the Binding of Importin 11 to HPV 16 E2 
 
In order to analyze the binding of HPV 16 E2 protein to importin 11, isolation 
assay was used in which GST-16cE2 was immobilized on glutathione sepharose 
beads and incubated with HeLa cytosol extracts. Analysis of the proteins bound 
to the beads after the procedure showed that no importin 11 could be detected in 
the elutions after incubation with either GST-16cE2 or GST (Fig. 9A; lanes 1 and 
2, respectively) and furthermore, importin 11 was not depleted from HeLa cytosol 
extract following the incubation with GST-16cE2 or GST (Fig. 9A; lanes 4 and 5, 
respectively), remaining at similar concentration as it was before the procedure 
(compare the importin 11 band at 112.5 KDa in lanes 3, 4 and 5 of Fig. 9A). This 
result shows that the binding of importin 11 to GST-16cE2 could not be detected 
using the isolation assay. As a control for this assay, another isolation assay was 
performed adding M9-GST as a control and using anti-kapβ2 antibody for 
detection. Kapβ2 binds strongly to M9-GST, its specific cargo (Fig. 10A; lane 3) 
while at the same time analysis of HeLa cytosol extract after the isolation 
procedure shows that Kapβ2 is depleted from HeLa cytosol after incubation with 
M9-GST (Fig. 10A, lane 7) but not after incubation with GST-16cE2  or GST (Fig. 
10A, lanes 5 and 6, respectively). The presence of Kapβ2 band at 102 KDa in 
lanes 1 and 2 indicates non-specific binding of Kapβ2 to GST-16cE2 and GST; 
however, given the fact that the Kapβ2 band in lane 3 is stronger and Kapβ2 is 
depleted from HeLa cytosol following the incubation with M9-GST, it could be 
concluded that the isolation assay procedure was valid and specific karyopherins 
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could be isolated from HeLa cytosol extracts using GST fusion proteins with 
cargoes or NLSs. As an additional control, the GST fusion proteins used in 
isolation assays were analyzed by SDS-PAGE and Coomassie Brilliant blue 
staining. As shown in Fig. 9B and 10B, the proteins are expressed at relatively 
similar concentrations and were present on glutathione sepharose beads used in 
these experiments. Overall, isolation assay experiments fail to answer the 
question of whether importin 11 binds HPV 16 E2.  
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Figure 9: Isolation Assay Does Not Show Binding of Importin 11 
to GST-16cE2 
 
A: GST-16cE2 (lane 1) or GST (lane 2) were immobilized on glutathione 
sepharose beads and incubated with HeLa cytosol extracts. Bound proteins were 
eluted and analyzed via immunoblotting with anti-importin 11 antibody. Importin 
11 present in the HeLa cytosol extract before the procedure is shown in lane 3, 
while importin 11 remaining in the unbound fraction after binding to GST-16cE2 
or GST is shown in lanes 4 and 5, respectively. 
 
B: GST-16cE2 (lane 1) and GST (lane 2) bound to glutathione sepharose beads 
used in importin 11 isolation experiment are detected with Coomassie Brilliant 
blue staining. 
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Figure 10: Isolation Assay Demonstrates Binding of Karyopherin 
β2 to M9-GST 
 
A: GST-16cE2 (lane 1), GST (lane 2) or M9-GST (lane 3) were immobilized on 
glutathione sepharose beads and incubated with HeLa cytosol extracts. Bound 
proteins were eluted and analyzed via immunoblotting with anti-kapβ2 antibody. 
Karyopherin β2 present in the HeLa cytosol extract before the procedure is 
shown in lane 4, while karyopherin β2 remaining in the unbound fraction after 
binding to GST-16cE2, GST, or M9-GST is shown in lanes 5, 6 and 7, 
respectively. Note the depletion of Kapβ2 from HeLa cytosol after incubation with 
M9-GST (red arrow). 
 
B: GST-16cE2 (lane 1), GST (lane 2) and M9-GST (lane 3) bound to glutathione 
sepharose beads used in karyopherin β2 isolation experiment are detected with 
Coomassie Brilliant blue staining. 
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In Solution Binding Assay to Test the Binding of Importin 11 to HPV 16 E2 
 
This assay was another way to test the binding of HPV 16 E2 and importin 11 in 
vitro. The advantage of this method over the isolation or immunoprecipitation 
assay is that since importin 11 is being expressed as a 6His-tagged fusion 
protein in E. coli cells, it could not have bound any of its natural cargoes that 
would normally be present in HeLa cells or HeLa cytosol extracts. In theory, 
competition with natural cargoes could have prevented the binding of importin 11 
to HPV 16 E2. 
 
The results of this experiment show that GST-E2 does not bind 6His-importin 11 
(Fig. 11, lane 1); however, GST-UbcM2 did (lane 2, importin 11 band at 112 
KDa). UbcM2 is the natural cargo for importin 11 (140) and provides a positive 
control for this experiment. All GST fusion proteins used in the binding 
experiment with 6His-importin 11 were properly expressed and immobilized on 
glutathione sepharose beads at approximately similar concentrations (Fig. 12). 
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Figure 11: In Solution Binding Assay Does not Show Binding of 
GST-16E2 to 6His-importin 11 but Confirms Binding of GST-
UbcM2 to 6His-importin 11 
 
GST-16E2 (lane 1), GST-UbcM2 (lane 2), or GST (lane 3) were immobilized on 
glutathione sepharose beads and incubated with lysates of E. coli cells 
expressing 6His-importin 11. Bound proteins were eluted and importin 11 was 
detected by immunoblot with anti-importin 11 antibody. Lanes 4 and 5 show 
importin 11 present in E. coli lysates and HeLa cytosol extracts, respectively. 
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Figure 12: GST Fusion Proteins Used in GST-16E2 and 6His-
importin 11 Binding Assay are Properly Expressed and Bound to 
Glutathione Sepharose Beads 
 
GST-16E2 (lane 1), GST-UbcM2 (lane 2) and GST (lane 3) bound to glutathione 
sepharose beads used in binding assay with 6His-importin 11 are detected with 
Coomassie Brilliant blue staining. 
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Immunoprecipitation Assays to Test the Binding of Importin 11 to HPV 16 E2 
 
These assays were another way to test the binding of HPV 16 E2 and importin 
11 in vitro. The advantage of this method is that HPV 16 E2 protein is expressed 
in HeLa cells, its native environment, as opposed to being expressed in the 
bacterial expression system. In immunoprecipitation assay, HeLa cells were 
transiently transfected with EGFP-16cE2, EGFP-16E2 or EGFP-C1 plasmids to 
allow the expression of viral proteins. Cells were lysed and lysates were 
analyzed for binding of EGFP-16cE2 or EGFP-E2 to importin 11 by using either 
anti-EGFP or anti-importin 11 antibody along with protein A sepharose beads to 
precipitate binding complexes out of solution.  
 
In the first immunoprecipitation experiment, potential binding complexes were 
immunoprecipitated with anti-EGFP antibody and proteins bound to protein A 
sepharose beads were analyzed with anti-importin 11 antibody (Fig. 13).  The 
results show that neither EGFP-16cE2 (lane 1), nor EGFP-16E2 (lane 7) bound 
importin 11, similarly to EGFP negative control (lane 3). Importin 11 was 
expressed in transiently transfected HeLa cells (lanes 9, 10 and 11), although at 
lower levels than in untransfected HeLa cells or commercially available HeLa 
cytosol extract (lanes 4 and 5). Since transfection reagents and conditions can 
slow down the rate of cell culture growth and cellular metabolism, lower levels of 
protein expression could be expected. Mock immunoprecipitation reactions, 
where no anti-EGFP antibody was added, were included to control for non-
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specific binding of importin 11 to protein A sepharose beads. No non-specific 
binding was detected (lanes 2 and 8).  
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Figure 13: Immunoprecipitation with Anti-EGFP Antibody Does 
not Demonstrate Binding of Importin 11 to EGFP-16cE2 or 
EGFP-16E2 
 
HeLa cells were transfected with EGFP-16cE2, EGFP-16E2 or EGFP-C1 
plasmids. Cell lysates were prepared 24 hours post transfection and incubated 
with anti-EGFP antibody and protein A sepharose beads. Bound proteins were 
eluted and elutions (EGFP-16cE2 (lane 1), EGFP-16E2 (lane 7), EGFP-C1 (lane 
3) were probed with anti-importin 11 antibody to detect potential importin 11 
binding. Control for non-specific binding to protein A sepharose beads where no 
anti-EGFP antibody was added are shown in lanes 2 (EGFP-16cE2) and 8 
(EGFP-16E2). Lanes 9, 10 and 11 show importin 11 present lysates of HeLa 
cells transfected with EGFP-16E2, EGFP-16-cE2 and EGFP-C1, respectively. 
Lanes 4 and 5 show importin 11 present in lysate of untransfected HeLa cells 
and in HeLa cytosol extract (ATCC), respectively. Lane 6 shows protein A band 
resulting from binding of secondary antibody to protein A. 
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In the second immunoprecipitation experiment, potential binding complexes were 
immunoprecipitated with anti-importin 11 antibody and proteins bound to protein 
A sepharose beads were analyzed with anti-EGFP antibody (Fig. 14). Since 
different antibodies have different affinities for their antigens, performing this 
“reversed” version of immunoprecipitation could provide results missed by the 
first experiment. The data show that EGFP-16cE2 and EGFP proteins are 
expressed very well in transiently transfected HeLa cells (lanes 4 and 5). 
However, EGFP-16cE2 appears to bind protein A sepharose beads in a non-
specific manner, as evidenced by the presence of EGFP-16cE2 in elutions 
regardless of whether anti-importin 11 antibody was added to the binding assay 
or not (lanes 1 and 2).  
 
Taken together, the results of the experiments described indicate the need for a 
different approach to answer the question of whether importin 11 binds HPV 16 
E2, provided such an interaction exists. Other researchers have used yeast two-
hybrid assays to study interactions of karyopherins with their cargoes. For 
example, one of importin 11’s natural cargoes, ribosomal protein L12, was 
identified in this manner (146). As such, it was decided to use yeast two-hybrid 
assay to study the putative interaction of importin 11 with HPV 16 E2. 
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Figure 14: Immunoprecipitation with Anti-importin 11 Antibody 
Does not Demonstrate Binding of Importin 11 to EGFP-16cE2 
Due to Non-specific Interaction of EGFP-16cE2 with Protein A 
Sepharose Beads 
 
HeLa cells were transfected with EGFP-16cE2 or EGFP-C1 plasmids. Cell 
lysates were prepared 24 hours post transfection and incubated with anti-
importin 11 antibody and protein A sepharose beads. Bound proteins were eluted 
and elutions (EGFP-16cE2 (lane 1), EGFP-C1 (lane 3) were probed with anti-
EGFP antibody to detect potential binding of EGFP-16cE2 or EGFP to importin 
11. Control for non-specific binding of EGFP-16cE2 to protein A sepharose 
beads where no anti-importin 11 antibody was added is shown in lane 2. Lanes 4 
and 5 show EGFP-16cE2 and EGFP, respectively, present in lysates of 
transfected HeLa cells, while lane 6 shows protein A band resulting from binding 
of secondary antibody to protein A.  
Note the presence of EGFP-16cE2 band in lane 2, indicating non-specific 
interaction of EGFP-16cE2 with protein A sepharose beads. 
  
 
 
 
 
 
         1            2             3            4            5            6         KDa 
100 
75 
50 
37 
25 
20 
 72
Yeast Two-Hybrid Assays 
 
Yeast two-hybrid assay is based on the principle that if two proteins of interest 
interact, two domains of the transcription factor, one of which is fused to each of 
the proteins of interest, come close together to produce a functional transcription 
factor that activates the expression of the reporter gene to produce a reporter 
protein that confers a new quality to the yeast cell in which the interaction is 
taking place. For example, reporter proteins may allow the cell to grow in the 
absence of certain nutrients or the yeast colony might change color. 
To investigate the interaction of HPV 16 E2 with importin 11 using yeast two-
hybrid assay, Saccharomyces cerevisiae YGR2 yeast cells were transformed 
with GBT10-importin 11 “bait” and pACTII-16cE2 “prey” plasmids and grown on 
SC-leu-trp media that allowed selection for double transformants (Fig. 15, panel 
A). Yeast cells transformed with GPA2 bait and fragment of adenylate cyclase 
prey, which are known to interact in a two-hybrid assay (147), were used as a 
positive control. The successfully transformed yeast colonies were replica plated 
onto SC-leu-trp-his plates. Since His3 enzyme was used as a reporter in this 
assay, cells would only grow on the medium lacking histidine if interaction 
between HPV 16 E2 and importin 11 took place. Additionally, 3-aminotriazol 
(3AT), which inhibits His3 enzyme, was added to the growth media to require the 
cells to express more selection marker.  
As can be seen in Fig. 15 (panels B-G), GBT10-importin 11/pACTII-16cE2 
double transformants failed to grow on the media lacking histidine, similar to the 
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negative control, whereas the positive control cells grew even in the presence of 
relatively high concentrations of 3AT. This indicates the lack of interaction 
between importin 11 and HPV 16cE2 proteins.  
In another experiment, filter lift β-galactosidase activity assay, was used to 
assess the same interaction using replica plates of the plate shown in panel A of 
Fig. 15. This assay (Fig. 16) shows lack of color change, suggesting the absence 
of interaction, for GBT10-importin 11/pACTII-16cE2 double transformants, while 
the positive control cells turned blue indicating production of X-gal.  
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Figure 15: Yeast Two-Hybrid Binding Assay Does not Show 
Binding of HPV 16 cE2 and Importin 11 
 
Saccharomyces cerevisiae YRG2 yeast cells were transformed with GBT10-
importin 11 bait plasmid and pACTII-16cE2 prey plasmid. The yeast were plated 
on –leu –trp +his SC plate to allow selection of double transformants (panel A) 
and then replica plated to –leu –trp –his SC plates with various concentration of 
3-aminotriazol (3AT) as indicated and grown at 30°C for 3 days (panels B-G). 
HIS3 reporter gene allows growth in the absence of histidine if interaction 
between the two proteins in question is present. 3AT inhibits HIS3 gene and 
requires the cells to express more selection marker. 
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Figure 16: Yeast Two-Hybrid Filter Lift β-galactosidase Activity 
Assay Does not Show Binding of HPV 16 cE2 and Importin 11 
 
Saccharomyces cerevisiae YGR2 yeast were transformed with plasmids as 
shown, grown on SC –trp-leu media for 24 hours at 30°C, transferred to a 
nitrocellulose filter and assessed for β-galactosidase activity. Blue color shows X-
gal production as an indicator of protein interaction. 
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In an attempt to promote a more stable interaction between importin 11 and HPV 
16 E2, we used importin 11 (78-975) N-terminal deletion mutant. This mutation 
was known to promote stable interactions between importin 11 and UbcM2, one 
of its natural cargoes, by preventing the binding of RanGTP to importin 11, thus 
allowing import complexes to remain in the nucleus where they could be 
successfully detected by yeast two-hybrid assay (140).  
Two-hybrid assays were performed with importin 11 (78-975) and either HPV 16 
cE2 (Fig. 17) or HPV 16 E2 (Fig. 18). Similarly to the two-hybrid assays with full 
length importin 11, the GBT10-importin 11 (78-975)/pACTII-16cE2 or pACTII-
16E2 double transformants failed to grow on the media lacking histidine, while 
the positive control cells grew successfully. 
In order to verify that importin 11 was properly expressed in S. cerevisiae, the 
cells were lysed and subjected to immunoblot with anti-importin 11 antibody. The 
results indicated that importin 11 (78-975) was expressed somewhat better than 
full length importin 11 (Fig. 19). 
Overall, the results of yeast two-hybrid assays did not provide evidence to 
support the direct interaction HPV 16 E2 protein and importin 11 karyopherin.  
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Figure 17: Yeast Two-Hybrid Binding Assay Does not Show 
Binding of HPV 16 cE2 and Importin 11 (78-975) 
 
Saccharomyces cerevisiae YRG2 yeast cells were transformed with GBT10-
importin 11 (78-975) bait plasmid and pACTII-16cE2 prey plasmid. The yeast 
were plated on –leu –trp +his SC plate to allow selection of double transformants 
(panel A) and then replica plated to –leu –trp –his SC plates with various 
concentration of 3-aminotriazol (3AT) as indicated and grown at 30°C for 3 days 
(panels B-G). HIS3 reporter gene allows growth in the absence of histidine if 
interaction between the two proteins in question is present. 3AT inhibits HIS3 
gene and requires the cells to express more selection marker. Importin 11 (78-
975) does not bind Ran-GTP and therefore allows potential import complexes to 
remain in the nucleus for better detection by two-hybrid assay. 
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Figure 18: Yeast Two-Hybrid Binding Assay Does not Show 
Binding of HPV 16 E2 and Importin 11 (78-975) 
 
Saccharomyces cerevisiae YRG2 yeast cells were transformed with GBT10-
importin 11 (78-975) bait plasmid and pACTII-16E2 prey plasmid. The yeast were 
plated on –leu –trp +his SC plate to allow selection of double transformants 
(panel A) and then replica plated to –leu –trp –his SC plates with various 
concentration of 3-aminotriazol (3AT) as indicated and grown at 30°C for 3 days 
(panels B-G). HIS3 reporter gene allows growth in the absence of histidine if 
interaction between the two proteins in question is present. 3AT inhibits HIS3 
gene and requires the cells to express more selection marker. Importin 11 (78-
975) does not bind Ran-GTP and therefore allows potential import complexes to 
remain in the nucleus for better detection by two-hybrid assay. 
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Figure 19: Importin 11 is Properly Expressed in S. cerevisiae 
Used in Yeast Two-Hybrid Assays 
 
S. cerevisiae YGR cells used in yeast two-hybrid assays with either importin 11 
(A) or importin 11 (78-975) (B) were grown in culture overnight at 30°C, pelleted 
and lysed in SDS-PAGE loading buffer by boiling for 10 minutes. The lysates 
were analyzed by immunoblot with anti-importin 11 antibody. Lane 1, cells 
transformed with pACT-16cE2 prey plasmid and pGBT10-importin 11 or 
pGBT10-importin 11 (78-975) bait plasmid; Lane 2, cells transformed with pACT-
16E2 prey plasmid and pGBT10-importin 11 or pGBT10-importin 11 (78-975) bait 
plasmid; Lane 3,non-transformed cells; Lane 4, HeLa cytosol extract. 
(*) indicates nonspecific interaction; red arrows indicate BD-importin 11 fusion 
proteins 
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To summarize, the results presented in this chapter led to two conclusions: a) 
importin 11 is necessary for nuclear import of HPV 16 E2, and b) importin 11 
does not seem to directly bind HPV 16 E2. To explain these observations, we 
hypothesized that HPV 16 E2 bound to importin 11 via an adapter protein. Such 
trimeric complexes are not uncommon; for example, in the classic nuclear import 
pathway, Kapα2β1 heterodimers are used as import receptors (30, 31). Moreover, 
several proteins have been described that use piggyback mechanism of nuclear 
import, whereby they bind to an adapter protein that, in turn, binds to the import 
receptor (152-154). Some NLS-defective mutants of HPV 11 E2 have been 
suggested to use piggybacking on HPV 11 E1 for their import (77). The question, 
then, was to identify putative candidates for the role of the adapter between HPV 
16 E2 and importin 11.  
 
 
 
 
 
 
 
 
 
 
 81
Investigation of the Role of UbcM2/UBE2E3 in the Nuclear Import of HPV 16 E2 
 
As mentioned before, one of the natural cargoes of importin 11 is murine E2-type 
ubiquitin-conjugating enzyme UbcM2. The human homolog of UbcM2 is UBE2E3 
and these two enzymes share 100% sequence homology (140, 148). HPV 16 E2 
protein is known to interact with UBE2K ubiquitin-conjugating enzyme (129). 
UbcM2/UBE2E3 and UBE2K share approximately 50% sequence homology and 
general tertiary structure (148, 149). Because of these similarities, we 
hypothesized that UbcM2/UBE2E3 could serve as an adapter protein in binding 
of HPV16 E2 to importin 11 during nuclear import of HPV 16 E2. Therefore, we 
tested whether HPV 16 E2 could bind UbcM2. 
The binding of HPV 16 E2 to UbcM2 was tested in the context of EGFP-16E2 
(Fig. 20) or EGFP-16cE2 (Fig. 22) and GST-UbcM2, with EGFP and GST serving 
as negative controls. The results revealed that EGFP-16cE2 specifically bound to 
GST-UbcM2 in vitro (Fig. 22, lane 1). The binding of EGFP-16E2 to GST-UbcM2 
was not detected; however, the level of expression of EGFP-16E2 in HeLa cells 
was much lower than the level of expression of EGFP-16cE2 (compare lanes 5 
and 7 in Fig. 20 and Fig. 22). Therefore, it is possible that the apparent difference 
in binding might have been caused by insufficient amounts of EGFP-16E2 in the 
HeLa lysates to detect binding. The amount of GST fusion proteins immobilized 
on glutathione sepharose beads was similar for GST-UbcM2 and GST in both 
experiments (Fig. 21 and 23). Overall, the results of these binding experiments 
strongly suggest that UbcM2/UBE2E3 can serve as an adapter protein in the 
 82
binding of HPV 16 E2 to importin 11 and that HPV 16 E2 is imported into the 
nucleus as a trimeric complex with importin 11 and UbcM2/UBE2E3. 
 
In summary, the results presented in this chapter revealed that a) the nuclear 
import of HPV 16 E2 protein requires importin 11 karyopherin and b) the import is 
most likely to occur as a trimeric complex where HPV 16 E2 binds to 
UbcM2/UBE2E3 ubiquitin-conjugating enzyme that binds to importin 11. 
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Figure 20: Low Expression of EGFP-16E2 May Interfere with 
Binding of EGFP-16E2 to GST-UbcM2 
 
GST-UbcM2 (lanes 1 and 2) or GST (lanes 3 and 4) were immobilized on 
glutathione sepharose beads and incubated with lysates of HeLa cells 
transfected with either EGFP-16E2 (lanes 1 and 3) or EGFP-C1 (lanes 2 and 4). 
Bound proteins were eluted and analyzed by immunoblot with anti-EGFP 
antibody. Lanes 5-8 are controls showing the presence of EGFP-E2 (lanes 5 and 
7) or EGFP (lanes 6 and 8) in HeLa cell lysates used in binding assays in lanes 
1-4, respectively. EGFP-16E2 bands are shown with the red arrow. 
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Figure 21: GST Fusion Proteins Used in GST-UbcM2 and EGFP-
E2 Binding Assay are Properly Expressed and Bound to 
Glutathione Sepharose Beads 
 
GST-UbcM2 (lane 1) and GST (lane 2) bound to glutathione sepharose beads 
used in binding assay with EGFP-E2 or EGFP are detected with Coomassie 
Brilliant blue staining. 
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Figure 22: Isolation Assay Demonstrates Binding of GST-UbcM2 
to EGFP-16cE2 
 
GST-UbcM2 (lanes 1 and 2) or GST (lanes 3 and 4) were immobilized on 
glutathione sepharose beads and incubated with lysates of HeLa cells 
transfected with either EGFP-16cE2 (lanes 1 and 3) or EGFP-C1 (lanes 2 and 4). 
Bound proteins were eluted and analyzed by immunoblot with anti-EGFP 
antibody. Lanes 5-8 are controls showing the presence of EGFP-cE2 (lanes 5 
and 7) or EGFP (lanes 6 and 8) in HeLa cell lysates used in binding assays in 
lanes 1-4, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 
100 
75 
50 
37 
25 
20 
200 
     1     2    3     4     5      6     7      8             KDa 
1 - EGFP-16cE2 + GST-UbcM2 elution 
2 - EGFP + GST-UbcM2 elution 
3 - EGFP-16cE2 + GST elution 
4 - EGFP + GST elution 
5 - EGFP-16cE2 + GST-UbcM2 lysate 
6 - EGFP + GST-UbcM2 lysate 
7 - EGFP-16cE2 + GST lysate 
8 - EGFP + GST lysate 
 86
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: GST Fusion Proteins Used in GST-UbcM2 and EGFP-
cE2 Binding Assay are Properly Expressed and Bound to 
Glutathione Sepharose Beads 
 
GST-UbcM2 (lane 1) and GST (lane 2) bound to glutathione sepharose beads 
used in binding assay with EGFP-E2 or EGFP are detected with Coomassie 
Brilliant blue staining. 
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Chapter 5 
Discussion 
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Papillomaviruses (PV) are small (55-60 nm in diameter), nonenveloped viruses 
with icosahedral capsid and double-stranded DNA genome of about 8 kb. PVs 
infect squamous basal epithelial cells with each type of PV exhibiting specific 
preference for a particular host organism and tissue type. Human 
papillomaviruses (HPV) are very diverse and cause a wide range of disease, 
most importantly, cancer. Most of HPVs belong to Alpha and Beta genera and 
they are commonly classified into low risk and high risk groups based on their 
propensity to cause cancer. The low risk types (e.g. HPV 6 and 11) cause mostly 
benign genital warts, whereas the infection with high risk types (e.g. HPV 16, 18, 
31, 45) often results in the development of anogenital cancers, such as cervical 
cancer. 
 
This work focused on HPV E2 protein. This protein is the major transcriptional 
regulator that is involved in the regulation of expression of viral E6 and E7 
oncogenes and the loss of E2 contributes to progression of the infected cell 
towards cancer. E2 functions to tether the viral genome to the host chromosomes 
in mitosis thus allowing for the proper retention, maintenance and partitioning of 
the viral genome. In addition, E2 interacts with a multitude of host cell’s gene 
products, including those involved in apoptosis, cell proliferation and 
differentiation, gene transcription, RNA processing, ubiquitination and 
degradation of proteins and intracellular transport. Overall, E2 is a potent 
regulatory protein that allows the cells to maintain an environment conducive to a 
successful replicative viral cycle. 
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Since E2 proteins are synthesized outside of the nucleus, they need to be 
transported into the nucleus to perform their functions. The present study 
focused on the nuclear import of high risk HPV 16 E2 protein. Previous research 
in the Moroianu lab has identified an alpha-helical NLS in the C-terminal (DNA-
binding) domain of HPV 16 E2 (75). This NLS, 298LKCLRYRFKKH308, overlaps 
with the alpha helix involved in DNA binding and it is partially conserved in high 
risk HPV 18 and not conserved in low risk HPV 11. Here, we continued the 
analysis of the nuclear import pathway(s) used by HPV 16 E2.  
 
In the first part of this research project, mutational analysis of several residues 
within the C-terminal NLS and elsewhere in the C-terminal domain of HPV 16 E2 
was performed in order to determine if the residues in question played a role in 
the function of the NLS. The K299A mutant demonstrated less robust nuclear 
import ability that the wild type protein. This residue is highly conserved among 
the PV E2 proteins; including both high and low risk HPV types and non-human 
PVs (92). Lysines and arginines, positively charged residues, are typically found 
in NLSs, therefore it is reasonable to assume that K299 may be contributing its 
charge to the NLS’s receptor-binding interface. Also, high degree of K299 
conservation suggests that this residue could be functionally important and, given 
its location within the DNA-binding alpha-helix, contribute to the formation of E2-
DNA contact interface. Since the alpha-helical NLS of HPV 16 E2, unlike 
classical NLS, must maintain proper secondary structure in order to function (75), 
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mutations of the conserved residues that undermine the helical folding are 
expected to reduce the NLS’s functional fitness. 
 
The K299A mutation affected the nuclear import of EGFP-16E2 more than the 
nuclear import of EGFP-16cE2. This could be explained by the fact that EGFP-
16cE2 is smaller and has a much longer half-life due to the absence of the 
transactivation domain that is involved in E2 degradation (121). As such, EGFP-
16cE2 is generally imported into the nucleus more efficiently that EGFP-16E2 
(compare the import of wild type proteins, Table 1). Therefore, the absence of an 
extra lysine with its positive charge plays a less important role in the context of 
EGFP-16cE2 than in the context of EGFP-16E2. However, even for the import of 
EGFP-16cE2, a modest reduction in the NLS function was observed for K299A 
mutant. 
 
The C300A mutation resulted in a modest decrease in the nuclear import of 
EGFP-16E2 and almost no change in the nuclear import of EGFP-16cE2. This 
residue, like K299, is highly conserved among a variety of PVs (92) and could be 
involved in the maintenance of the proper alpha-helical structure and in the 
contacts between E2 and DNA. If this mutation results in the somewhat distorted 
alpha-helix, it is reasonable to expect a less functional NLS than in the case of a 
wild type protein. The more pronounced effect of C300A mutation in the context 
of EGFP-16E2 vs. EGFP-16cE2 could be explained by the same reasons as for 
the K299A mutants above. 
 91
The 327KHK329 sequence is located 19 residues downstream of the C-terminal 
NLS of HPV 16 E2. Structurally, it is a part of the disordered loop between β2 
and β3 strands of the C-terminal domain (Fig. 1). The K329 residue is fairly 
conserved among multiple PV E2 proteins, either remaining unchanged or being 
replaced by arginine, another positively charged amino acid. The other two 
residues of the 327KHK329 are not conserved (92). As mentioned earlier, lysine 
residues are often found in NLSs and histidine residue with its imidazole R group 
is often involved in protein-protein interactions. As such, it was reasonable to 
assume that KHK sequence could be important for the nuclear import of HPV 16 
E2. Indeed, when KHK was mutated to AAA, there was a significant drop in the 
nuclear localization of the HPV16 E2 protein, both in the context of EGFP-16E2 
and EGFP-16cE2. As with the mutants described before, the EGFP-16cE2 fusion 
proteins localized to the nucleus more than the EGFP-16E2 proteins. It appears 
that the 327KHK329 acts as an “enhancer” sequence for the C-terminal NLS of 
HPV 16 E2, providing additional positively charged residues to the receptor-
binding interface. The sequence’s position within a flexible and disordered loop 
potentially allows it to bind to a different location on the import receptor that the 
main NLS binding site increasing the strength of the interaction. 
 
Papillomavirus E2 proteins normally exist in solution as dimers. As described in 
Chapter 1, dimerization occurs via both N-terminal and C-terminal domain 
residues. In the case of C-terminal domain, dimerization is required for proper 
DNA binding. A critical tryptophan residue, W319 in HPV 16 E2, is called the 
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“tryptophan bridge” and mutations in this residue have been known to disrupt the 
dimerization of the C-terminal domain (100). We hypothesized that if the HPV 16 
E2 dimers form in the cytoplasm, prior to the protein’s entry into the nucleus, the 
two NLSs of the dimeric protein could act cooperatively in the nuclear import of 
HPV 16 E2. The results show that the W319G mutant demonstrates a significant 
mislocalization in the context of EGFP-16cE2 but the localization is only modestly 
affected in the context of EGFP-16E2. This could be explained as follows. In the 
EGFP-16E2 W319G mutant, the dimerization via the transactivation domain is 
unaffected, and the two NLSs are able to act cooperatively, similar to the wild 
type protein. On the other hand, in the EGFP-16cE2, the disruption of the dimer 
interface leaves only one NLS per molecule. This may lead to decreased affinity 
of the protein for the import receptor and mislocalization to the cytoplasm. 
Additionally, it is possible that the monomeric EGFP-16cE2 is unable to maintain 
the proper secondary and/or tertiary structure. Since the alpha-helical NLS of 
HPV 16 E2 depends on its structure for proper function, even a partially 
misfolded mutant should have its nuclear import negatively affected.  
EGFP-16cE2 monomer at 42 KDa is almost at the exclusion limit of the NPC. 
However, the nuclear entry of the monomeric EGFP-16cE2 W319G mutant into 
the nucleus by passive diffusion seems unlikely in the light of the fact that only 
37.6% of EGFP negative control protein localizes to the nucleus, indicating that 
passive diffusion through the NPC is a rather slow and inefficient process 
compared to karyopherin-driven transport. If EGFP-16cE2 W319G proteins were 
in fact entering the nucleus by passive diffusion, the percentage of them 
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localizing to the nucleus would be similar to that of EGFP negative control, and 
perhaps even lower, given the fact that EGFP-16cE2 monomer is larger than 
EGFP (42 v. 32.7 KDa, respectively). Since the observed percent of nuclear 
localized EGFP-16cE2 W319G is 59.7%, it is unlikely that it enters the nucleus 
by passive diffusion, but rather it utilizes karyopherin-driven import pathway, 
albeit with much less efficiency than the wild type protein for the aforementioned 
reasons. As such, the data strongly suggest that dimerization plays an important 
role in the nuclear import of HPV 16 E2 protein. In the future, 2xEGFP-16cE2 
W319G fusion protein could be generated that would clearly be too large to enter 
the nucleus by passive diffusion. Also, the disruption of dimerization could be 
verified by bimolecular fluorescence complementation technique (BiFC) whereby 
two non-fluorescent halves of a green fluorescent protein (GFP) variant are fused 
to two monomers. The dimerization leads to the reconstitution of the GFP to a 
fluorescent molecule. This technique has been successfully used to study the 
formation of homodimers (159, 160). Also, other residues that had been 
determined to be involved in the formation of C-terminal dimers (see Chapter 1) 
could be mutated and studied for their role in the nuclear import of HPV 16 E2. 
 
In addition to the analysis of the HPV 16 E2 mutants mentioned before, other 
mutants were generated and analyzed. These included the mutations of the 
hydrophobic residues within the NLS (L301A and F305A). These residues are 
partially conserved (92) and, in some known NLSs, hydrophobic residues were 
shown to be critical for the NLS function (155, 156). However, in the case of HPV 
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16 E2, the hydrophobic residues within the NLS did not appear to play a role in 
nuclear import. The results of experiments with these mutants, as well as with 
other mutants, are described in Appendix A. 
 
To summarize, in the first part of this research project, we have identified several 
residues within the C-terminal domain of HPV 16 E2 protein that play an 
important role in the protein’s nuclear import. We have shown that the K299 
residue increases the propensity of HPV 16 E2 to enter the nucleus, presumably 
by providing an additional positive charge to the import receptor binding interface. 
The C300 residue was found to be modestly important to the function of the NLS; 
presumably by contributing to the maintenance of the proper alpha-helical shape 
of the NLS.  We have identified the NLS “enhancer” sequence, 327KHK329, which 
significantly increases the robustness of the nuclear import of HPV 16 E2 
presumably by acting as an additional element in the import receptor binding 
interface. Finally, this research demonstrated the importance of dimerization for 
the nuclear import of HPV 16 E2. 
 
In the second part of this research project, we focused on identifying the nuclear 
import receptor for the alpha-helical C-terminal NLS of HPV 16 E2 protein. 
Because of the structural similarity between the HPV 16 E2 NLS and the alpha 
helical NLS of MA domain of Gag protein of Rous sarcoma virus (RSV) (137), we 
focused on importin 11, which was found to be an import receptor for the MA 
domain (138). 
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The nuclear import assays demonstrated that importin 11 was required for the 
nuclear import of GST-16cE2 in vitro. At the same time, various in vitro assays, 
including isolation assays, in solution binding assays, immunoprecipitation 
assays and yeast two-hybrid assays, failed to demonstrate the direct binding of 
HPV 16 E2 to importin 11.  
 
As described in Chapter 4, based on the results of nuclear import assays and in 
vitro assays, we hypothesized that an adapter protein was involved in the nuclear 
import of HPV 16 E2. Furthermore, based on the analysis of the literature, in 
particular based on the results of the studies of the binding interactions of 
importin 11 and HPV 16 E2 (129, 140), we identified UbcM2/UBE2E3 E2-type 
ubiquitin-conjugating enzyme as a putative adapter protein for the nuclear import 
of HPV 16 E2. The binding assays revealed that EGFP-16cE2 bound GST-
UbcM2 in vitro suggesting that our hypothesis was correct. Moreover, 
UbcM2/UBE2E3 is present in HeLa cells (157). However, several questions 
remain. 
 
First, the existence of trimeric complex of HPV 16 E2, UbcM2/UBE2E3 and 
importin 11 will need to be demonstrated. In vitro, this could be done by 
immobilizing GST-16cE2 (or GST-16E2) on glutathione sepharose beads and 
incubating the beads with untagged UbcM2, followed by incubation with 6His-
importin 11 and detection with anti-importin 11 antibody. Also, the requirement 
for the trimeric complex could be demonstrated in a nuclear import assay with 
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importin 11 and UbcM2 used in the presence of RanGDP. In vivo, a cell line that 
stably expresses HPV 16 E2 could be used to study its interactions. Our attempts 
to create a HeLa cell line stably expressing EGFP-16E2 were not successful; 
however, U2OS cell line stably expressing HPV 16 E2 exists (122). 
 
Second, the use of UbcM2/UBE2E3 as an adapter is interesting because it is not 
a karyopherin. As such, the import mechanism of HPV 16 E2 does not resemble 
the classic import pathway. However, the presence of a well-defined NLS in HPV 
16 E2 differentiates its import from described “piggyback” import mechanisms 
wherein a protein that lacks the NLS of its own piggy backs on a NLS-containing 
protein. Therefore, HPV 16 E2 seems to be using a unique and previously 
undescribed import mechanism. 
 
Why would such a mechanism exist? As described in Chapter 1, papillomavirus 
proteins use a variety of import pathways, both classic and non-classic, because 
they evolved to adapt the host cell’s molecular machinery to successfully 
propagate. In this regard, the fact that HPV 16 E2 uses a previously undescribed 
pathway is not surprising.  
 
The evolution of HPV 16 E2 to use UbcM2/UBE2E3 for its nuclear import may 
not be entirely random. HPV 16 E2 is an important regulator of DNA replication 
and gene expression. As such, its presence in the nucleus must be precisely 
controlled. Using UbcM2/UBE2E3 as a part of the import complex allows for a 
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control mechanism since UbcM2/UBE2E3 is imported only in ubiquitinated state 
(157) and it is conceivable that HPV 16 E2’s nuclear entry is controlled by 
alternating the ubiquitination state of UbcM2/UBE2E3. Binding of ubiquitinated 
UbcM2/UBE2E3 to HPV 16 E2 may lead to specific ubiquitination of E2 that 
favors its interaction with importin 11. Also, PV E2 proteins are targeted for 
degradation by SCFSkp2 ubiquitin ligase which acts on the residues in the 
transactivation domain. Although highly speculative, it is intriguing to think that a 
coupling of a ubiquitin-charged ubiquitin-conjugating enzyme (UbcM2/UBE2E3) 
as an import receptor binding the C-terminal NLS and ubiquitin ligase binding the 
N-terminal domain could provide a way to precisely control the amount of HPV 
16 E2 entering the nucleus. In this view, the deletion of the transactivation 
domain in 16cE2 would remove this control and lead to more protein localizing to 
the nucleus, a result that was observed in transient transfections described in 
Chapter 3. 
 
In addition to the regulation of the nuclear import of HPV 16 E2, the trimeric 
complex of importin 11 and UbcM2/UBE2E3 may perform a chaperone function 
to protect HPV 16 E2 during import and to ensure it is not misfolded. 
Karyopherins are known to have chaperone functions for proteins with exposed 
basic domains (158). 
 
Our results do not contradict the data by Bian and Wilson (79) who found that 
HPV 16 E2 bound preferentially to importin α5 in vitro, because it is possible for a 
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protein to bind more than one karyopherin and also because those researchers 
did not perform any functional assays demonstrating the requirement for importin 
α5 for nuclear import of HPV 16 E2 and did not detect the presence of importin 
α5 in the HeLa cell extract (79). If it was present in cells it could transport HPV 16 
E2 into the nucleus in the presence of importin β/karyopherin β1. 
 
Looking into the future, several avenues of research may arise from these results. 
First of all, the existence of the trimeric complex of HPV 16 E2, importin 11 and 
UbcM2/UBE2E3 will need to be determined, as described above. Second, it 
would be interesting to test the mutant forms of HPV 16 E2 and cE2 generated 
during this project and other mutants that alter nuclear import of HPV 16 E2 (75) 
for their ability to bind UbcM2/UBE2E3 and/or importin 11 to determine the 
specific molecular interactions. Third, it would be intriguing to study the nuclear 
import pathways of E2 proteins of other PV types. Since they have different NLSs, 
they are likely to bind different karyopherins and/or use different adapters. Finally, 
it is likely that there is a link between the regulation of the nuclear import of HPV 
16 E2 and its function as a transcriptional regulator. It would be interesting to 
investigate the putative relationship between the nuclear import of HPV 16 E2 
and the regulation of the cell cycle. HPV 16 E2 has been found to bind cyclin-
dependent kinase-like3 protein (132) and it is a regulator of viral oncogene E7 
that is involved in cell cycle control via its interaction with cyclins, CDKs, HDACs 
and other cellular targets as discussed in Chapter 1. E7-induced destabilization 
of pRb, for example, is dependent upon the involvement of E2-25K ubiquitin 
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carrier protein, also known as UBE2K, which is one of the proteins HPV 16 E2 is 
known to interact with (129, 150). Additionally, importin α and proteins containing 
classical bi-partite NLSs are known to be involved in G1/S cell cycle progression 
in S. cerevisiae (151), which opens the possibility that importin 11 and HPV 16 
E2 might also be involved in the cell cycle control in some capacity.  
 
In conclusion, this research has contributed to the understanding of the 
mechanisms of nuclear import of high risk HPV 16 E2 protein. The mutational 
analysis has continued the past research to further elucidate the properties of the 
novel, alpha-helical, C-terminal NLS and also looked at the role of the 
dimerization state of HPV 16 E2 protein in its nuclear import. As described in 
Chapter 1, PV proteins use a variety of nuclear import pathways. While some of 
them (for example, L1, L2 and E6) use the classical import pathway involving 
Kapα2β1 heterodimer, others rely upon non-classical import pathways and use a 
variety of karyopherins in the alpha and beta karyopherin families (for example, 
L2, E1 and E6) or bind FG nucleoporins directly (for example, E7). In comparison 
with previously described import pathways of PV proteins, HPV 16 E2 uses a 
different import strategy. The search for the HPV 16 E2 import receptor resulted 
in the discovery of importin 11 karyopherin. The data suggest a previously 
undescribed import pathway whereby UbcM2/UBE2E3 E2-type ubiquitin-
conjugating enzyme is used as an adapter between HPV 16 E2 and importin 11 
karyopherin. To our knowledge, this is the first description of a nuclear import 
 100
mechanism where a NLS-containing protein binds an ubiquitin-conjugating 
enzyme adapter in a complex with an importin. 
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Appendix A 
Investigation of the Role of L301A, F305A, V326STOP and 
V331STOP Mutations in the Nuclear Import of HPV 16 E2 Protein 
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L301 and F305 are hydrophobic residues that are located within the previously 
established C-terminal NLS of HPV 16 E2 (75) (Fig. 1). The role of these 
residues in the nuclear import of HPV 16 E2 protein was investigated using 
transient transfections in HeLa cells in the context of EGFP-16E2 and EGFP-
16cE2 L301A and F305A mutants. These experiments were performed by Erin 
Groden under my supervision. The results indicated that neither of the two 
mutations affected the nuclear localization of HPV 16 E2 as both mutants 
displayed nuclear localization similar to wild type proteins (Fig. A1). These results 
determined that these hydrophobic residues do not play a role in the nuclear 
import of HPV 16 E2. 
 
V326STOP and A331STOP mutants were generated in order to investigate 
putative requirement for 327KHK329 sequence in the nuclear import of HPV 16 E2. 
As can be seen in Fig. 1, these mutants generated truncated proteins that either 
included the 327KHK329 sequence or excluded it. The results demonstrated that 
these mutations resulted in pancellular localization similar to EGFP negative 
control, both in the context of EGFP-16E2 or EGFP-cE2 (Fig. A2). The reason for 
this is likely to be that the tertiary or even secondary structure of the C-terminal 
domain could not be maintained in the truncated proteins resulting in non-
functional NLS. As a result of these observations, we decided to generate 
KHK327AAA mutants which allowed to investigate the role of 327KHK329 
sequence in the nuclear import of HPV 16 E2 while allowing to maintain the 
general folding of the C-terminal domain. 
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Figure A1: L301A and F305A Mutations Do not Alter the Nuclear 
Localization of EGFP-16cE2 or EGFP-16E2 
 
A. HeLa cells were transfected with EGFP-C1 (panels A and B), EGFP-16cE2 
(panels C and D), or EGFP-16cE2 L301A (panels E and F) plasmids. 
B. HeLa cells were transfected with EGFP-C1 (panels A and B), EGFP-16E2 
(panels C and D), or EGFP-16E2 L301A (panels E and F) plasmids. 
C. HeLa cells were transfected with EGFP-C1 (panels A and B), EGFP-16cE2 
(panels C and D), or EGFP-16cE2 F305A (panels E and F) plasmids.  
D. HeLa cells were transfected with EGFP-C1 (panels A and B), EGFP-16E2 
(panels C and D), or EGFP-16E2 F305A (panels E and F) plasmids. 
All cells were examined by fluorescent microscopy 24 hours post transfection. 
Panels B, D and F represent the fluorescence of EGFP. Panels A, C and E 
represent the DAPI staining of the nuclei. (Erin Groden, Biology Honors Thesis, 
2010.) 
A B 
C D 
       DAPI                EGFP                                   DAPI               EGFP 
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Figure A2: V326STOP and A331STOP Mutations Change the 
Localization of EGFP-16cE2 and EGFP-16E2 from Nuclear to 
Pancellular 
 
A. HeLa cells were transfected with EGFP-C1 (panels A and B), EGFP-16cE2 
(panels C and D), EGFP-16cE2 V326STOP (panels E and F), or EGFP-16cE2 
A331STOP (panels G and H) plasmids. 
B. HeLa cells were transfected with EGFP-C1 (panels A and B), EGFP-16E2 
(panels C and D), EGFP-16E2 V326STOP (panels E and F), or EGFP-16E2 
A331STOP (panels G and H) plasmids. 
All cells were examined by fluorescent microscopy 24 hours post transfection. 
Panels B, D, F and H represent the fluorescence of EGFP. Panels A, C, E and G 
represent the DAPI staining of the nuclei. (Erin Groden, Biology Honors Thesis, 
2010.) 
 
 
 
 
 
 
          DAPI             EGFP                                   DAPI               EGFP 
A B 
 105
Literature Cited 
1. Doorbar, J., Molecular biology of human papillomavirus infection and 
cervical cancer. Clin Sci (Lond), 2006. 110(5): p. 525-41. 
2. Sapp, M. and Bienkowska-Haba, M., Viral entry mechanisms: human 
papillomavirus and a long journey from extracellular matrix to the nucleus. 
FEBS J, 2009. 276(24): p. 7-16. 
3. Spoden, G., Freitag, K., Husmann, M., Boller, K., Sapp, M., Lambert, C., 
and Florin, L., Clathrin- and caveolin-independent entry of human 
papillomavirus type 16--involvement of tetraspanin-enriched microdomains 
(TEMs). PLoS One, 2008. 3(10): p. e3313. 
4. Day, P.M., Lowy, D.R., and Schiller, J.T., Papillomaviruses infect cells via 
a clathrin-dependent pathway. Virology, 2003. 307(1): p. 1-11. 
5. Sapp, M. and Day, P.M., Structure, attachment and entry of polyoma- and 
papillomaviruses. Virology, 2009. 384(2): p. 400-9. 
6. Rector, A. and Van Ranst, M., Animal papillomaviruses. Virology, 2013. 
445(1-2): p. 213-23. 
7. Schulz, E., Gottschling, M., Bravo, I. G., Wittstatt, U., Stockfleth, E., and 
Nindl, I., Genomic characterization of the first insectivoran papillomavirus 
reveals an unusually long, second non-coding region and indicates a close 
relationship to Betapapillomavirus. J Gen Virol, 2009. 90(Pt 3): p. 626-33. 
8. Van Doorslaer, K., Evolution of the papillomaviridae. Virology, 2013. 
445(1-2): p. 11-20. 
9. Bravo, I.G., Crusius, K., and A. Alonso, A., The E5 protein of the human 
papillomavirus type 16 modulates composition and dynamics of 
membrane lipids in keratinocytes. Arch Virol, 2005. 150(2): p. 231-46. 
10. de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U., and zur 
Hausen, H., Classification of papillomaviruses. Virology, 2004. 324(1): p. 
17-27. 
11. Bernard, H. U., Burk, R. D., Chen, Z., van Doorslaer, K., zur Hausen, H., 
and de Villiers, E. M., Classification of papillomaviruses (PVs) based on 
189 PV types and proposal of taxonomic amendments. Virology, 2010. 
401(1): p. 70-9. 
12. de Villiers, E.M., Cross-roads in the classification of papillomaviruses. 
Virology, 2013. 445(1-2): p. 2-10. 
13. Onon, T.S., History of human papillomavirus, warts and cancer: what do 
we know today? Best Pract Res Clin Obstet Gynaecol, 2011. 25(5): p. 
565-74. 
14. zur Hausen, H., Papillomaviruses in the causation of human cancers - a 
brief historical account. Virology, 2009. 384(2): p. 260-5. 
15. Longworth, M.S. and Laimins, L.A., Pathogenesis of human 
papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev, 2004. 
68(2): p. 362-72. 
16. Orlando, P. A., Gatenby, R. A., Giuliano, A. R., and Brown, J. S., 
Evolutionary ecology of human papillomavirus: trade-offs, coexistence, 
 106
and origins of high-risk and low-risk types. J Infect Dis, 2011. 205(2): p. 
272-9. 
17. Modis, Y., Trus, B.L., and Harrison, S.C., Atomic model of the 
papillomavirus capsid. EMBO J, 2002. 21(18): p. 4754-62. 
18. Frati, E., Bianchi, S., Colzani, D., Zappa, A., Orlando, G., and Tanzi, E., 
Genetic variability in the major capsid L1 protein of human papillomavirus 
type 16 (HPV-16) and 18 (HPV-18). Infect Genet Evol, 2011. 11(8): p. 
2119-24. 
19. Hughes, F.J. and Romanos, M.A., E1 protein of human papillomavirus is a 
DNA helicase/ATPase. Nucleic Acids Res, 1993. 21(25): p. 5817-23. 
20. Deng, W., Lin, B. Y., Jin, G., Wheeler, C. G., Ma, T., Harper, J. W., Broker, 
T. R., and Chow, L. T., Cyclin/CDK regulates the nucleocytoplasmic 
localization of the human papillomavirus E1 DNA helicase. J Virol, 2004. 
78(24): p. 13954-65. 
21. McBride, A.A., The papillomavirus E2 proteins. Virology, 2013. 445(1-2): p. 
57-79. 
22. McIntosh, P. B., Martin, S. R., Jackson, D. J., Khan, J., Isaacson, E. R., 
Calder, L., Raj, K., Griffin, H. M., Wang, Q., Laskey, P., Eccleston, J. F., 
and Doorbar, J., Structural analysis reveals an amyloid form of the human 
papillomavirus type 16 E1--E4 protein and provides a molecular basis for 
its accumulation. J Virol, 2008. 82(16): p. 8196-203. 
23. Moody, C.A. and Laimins, L.A., Human papillomavirus oncoproteins: 
pathways to transformation. Nat Rev Cancer, 2010. 10(8): p. 550-60. 
24. Bienkowska-Haba, M., Patel, H.D., and Sapp, M., Target cell cyclophilins 
facilitate human papillomavirus type 16 infection. PLoS Pathog, 2009. 
5(7): p. e1000524. 
25. Munger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., 
Owens, M., Grace, M., and Huh, K., Mechanisms of human 
papillomavirus-induced oncogenesis. J Virol, 2004. 78(21): p. 11451-60. 
26. Bordeaux, J., Forte, S., Harding, E., Darshan, M. S., Klucevsek, K., and 
Moroianu, J., The L2 minor capsid protein of low-risk human 
papillomavirus type 11 interacts with host nuclear import receptors and 
viral DNA. J Virol, 2006. 80(16): p. 8259-62. 
27. Klucevsek, K., Daley, J., Darshan, M. S., Bordeaux, J., and Moroianu, J., 
Nuclear import strategies of high-risk HPV18 L2 minor capsid protein. 
Virology, 2006. 352(1): p. 200-8. 
28. Darshan, M. S., Lucchi, J., Harding, E., and Moroianu, J., The L2 minor 
capsid protein of human papillomavirus type 16 interacts with a network of 
nuclear import receptors. J Virol, 2004. 78(22): p. 12179-88. 
29. Fay, A., Yutzy, W. H. t., Roden, R. B., and Moroianu, J., The positively 
charged termini of L2 minor capsid protein required for bovine 
papillomavirus infection function separately in nuclear import and DNA 
binding. J Virol, 2004. 78(24): p. 13447-54. 
30. Merle, E., Rose, R. C., LeRoux, L., and Moroianu, J., Nuclear import of 
HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 
heterodimers. J Cell Biochem, 1999. 74(4): p. 628-37. 
 107
31. Nelson, L. M., Rose, R. C., LeRoux, L., Lane, C., Bruya, K., and Moroianu, 
J., Nuclear import and DNA binding of human papillomavirus type 45 L1 
capsid protein. J Cell Biochem, 2000. 79(2): p. 225-38. 
32. Joyce, J. G., Tung, J. S., Przysiecki, C. T., Cook, J. C., Lehman, E. D., 
Sands, J. A., Jansen, K. U., and Keller, P. M., The L1 major capsid protein 
of human papillomavirus type 11 recombinant virus-like particles interacts 
with heparin and cell-surface glycosaminoglycans on human keratinocytes. 
J Biol Chem, 1999. 274(9): p. 5810-22. 
33. Hindmarsh, P.L. and Laimins, L.A., Mechanisms regulating expression of 
the HPV 31 L1 and L2 capsid proteins and pseudovirion entry. Virol J, 
2007. 4: p. 19. 
34. Jones, E.E. and Wells, S.I., Cervical cancer and human papillomaviruses: 
inactivation of retinoblastoma and other tumor suppressor pathways. Curr 
Mol Med, 2006. 6(7): p. 795-808. 
35. Jeon, S., Allen-Hoffmann, B.L., and Lambert, P.F., Integration of human 
papillomavirus type 16 into the human genome correlates with a selective 
growth advantage of cells. J Virol, 1995. 69(5): p. 2989-97. 
36. Thorland, E. C., Myers, S. L., Gostout, B. S., and Smith, D. I., Common 
fragile sites are preferential targets for HPV16 integrations in cervical 
tumors. Oncogene, 2003. 22(8): p. 1225-37. 
37. Pett, M. R., Alazawi, W. O., Roberts, I., Dowen, S., Smith, D. I., Stanley, M. 
A., and Coleman, N., Acquisition of high-level chromosomal instability is 
associated with integration of human papillomavirus type 16 in cervical 
keratinocytes. Cancer Res, 2004. 64(4): p. 1359-68. 
38. Stanley, M.A., Pett, M.R., and Coleman, N., HPV: from infection to cancer. 
Biochem Soc Trans, 2007. 35(Pt 6): p. 1456-60. 
39. Doorbar, J., The papillomavirus life cycle. J Clin Virol, 2005. 32 Suppl 1: p. 
S7-15. 
40. McLaughlin-Drubin, M.E. and Munger, K., Oncogenic activities of human 
papillomaviruses. Virus Res, 2009. 143(2): p. 195-208. 
41. Wise-Draper, T.M. and Wells, S.I., Papillomavirus E6 and E7 proteins and 
their cellular targets. Front Biosci, 2008. 13: p. 1003-17. 
42. Hebner, C.M. and Laimins, L.A., Human papillomaviruses: basic 
mechanisms of pathogenesis and oncogenicity. Rev Med Virol, 2006. 
16(2): p. 83-97. 
43. Schiller, J.T., Day, P.M., and Kines, R.C., Current understanding of the 
mechanism of HPV infection. Gynecol Oncol, 2010. 118(1 Suppl): p. S12-
7. 
44. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., and 
Wacholder, S., et al., Human papillomavirus and cervical cancer. Lancet, 
2007. 370(9590): p. 890-907. 
45. Chaturvedi, A.K., Beyond cervical cancer: burden of other HPV-related 
cancers among men and women. J Adolesc Health, 2010. 46(4 Suppl): p. 
S20-6. 
 108
46. Trottier, H. and Franco, E.L., Human papillomavirus and cervical cancer: 
burden of illness and basis for prevention. Am J Manag Care, 2006. 12(17 
Suppl): p. S462-72. 
47. Trottier, H., Mahmud, S., Prado, J. C., Sobrinho, J. S., Costa, M. C., 
Rohan, T. E., Villa, L. L., and Franco, E. L, Type-specific duration of 
human papillomavirus infection: implications for human papillomavirus 
screening and vaccination. J Infect Dis, 2008. 197(10): p. 1436-47. 
48. Zandberg, D. P., Bhargava, R., Badin, S., and Cullen, K. J., The role of 
human papillomavirus in nongenital cancers. CA Cancer J Clin, 2012. 
63(1): p. 57-81. 
49. Daud II, S.M., Ma Y, Shiboski S, Farhat S, and Moscicki AB., Association 
between toll-like receptor expression and human papillomavirus type 16 
persistence. Int J Cancer, 2010. 128(4): p. 879-886. 
50. Burk, R.D., Chen, Z., and Van Doorslaer, K., Human papillomaviruses: 
genetic basis of carcinogenicity. Public Health Genomics, 2009. 12(5-6): p. 
281-90. 
51. Palefsky, J., Biology of HPV in HIV infection. Adv Dent Res, 2006. 19(1): p. 
99-105. 
52. Aitchison, J.D. and Rout, M.P., The yeast nuclear pore complex and 
transport through it. Genetics, 2012. 190(3): p. 855-83. 
53. Rout, M.P. and Aitchison, J.D., The nuclear pore complex as a transport 
machine. J Biol Chem, 2001. 276(20): p. 16593-6. 
54. Wente, S.R. and Rout, M.P., The nuclear pore complex and nuclear 
transport. Cold Spring Harb Perspect Biol, 2010. 2(10): p. a000562. 
55. Moroianu, J., Nuclear import and export pathways. J Cell Biochem, 1999. 
Suppl 32-33: p. 76-83. 
56. Terry, L.J., Shows, E.B., and Wente, S.R., Crossing the nuclear envelope: 
hierarchical regulation of nucleocytoplasmic transport. Science, 2007. 
318(5855): p. 1412-6. 
57. Hetzer, M.W., Walther, T.C., and Mattaj, I.W., Pushing the envelope: 
structure, function, and dynamics of the nuclear periphery. Annu Rev Cell 
Dev Biol, 2005. 21: p. 347-80. 
58. Walde, S. and Kehlenbach, R.H., The Part and the Whole: functions of 
nucleoporins in nucleocytoplasmic transport. Trends Cell Biol, 2010. 20(8): 
p. 461-9. 
59. Pemberton, L.F. and Paschal, B.M., Mechanisms of receptor-mediated 
nuclear import and nuclear export. Traffic, 2005. 6(3): p. 187-98. 
60. Sorokin, A.V., Kim, E.R., and Ovchinnikov, L.P., Nucleocytoplasmic 
transport of proteins. Biochemistry (Mosc), 2007. 72(13): p. 1439-57. 
61. Fries, T., Betz, C., Sohn, K., Caesar, S., Schlenstedt, G., and Bailer, S. M., 
A novel conserved nuclear localization signal is recognized by a group of 
yeast importins. J Biol Chem, 2007. 282(27): p. 19292-301. 
62. Yoshida, K. and Blobel, G., The karyopherin Kap142p/Msn5p mediates 
nuclear import and nuclear export of different cargo proteins. J Cell Biol, 
2001. 152(4): p. 729-40. 
 109
63. Chook, Y.M. and Blobel, G., Karyopherins and nuclear import. Curr Opin 
Struct Biol, 2001. 11(6): p. 703-15. 
64. Moroianu, J., Nuclear import and export: transport factors, mechanisms 
and regulation. Crit Rev Eukaryot Gene Expr, 1999. 9(2): p. 89-106. 
65. Moroianu, J., Blobel, G., and Radu, A., Previously identified protein of 
uncertain function is karyopherin alpha and together with karyopherin beta 
docks import substrate at nuclear pore complexes. Proc Natl Acad Sci U S 
A, 1995. 92(6): p. 2008-11. 
66. Moroianu, J. and Blobel, G., Protein export from the nucleus requires the 
GTPase Ran and GTP hydrolysis. Proc Natl Acad Sci U S A, 1995. 
92(10): p. 4318-22. 
67. Nemergut, M.E. and Macara, I.G., Nuclear import of the ran exchange 
factor, RCC1, is mediated by at least two distinct mechanisms. J Cell Biol, 
2000. 149(4): p. 835-50. 
68. Nelson, L.M., Rose, R.C., and Moroianu, J., The L1 major capsid protein 
of human papillomavirus type 11 interacts with Kap beta2 and Kap beta3 
nuclear import receptors. Virology, 2003. 306(1): p. 162-9. 
69. Bird, G., O'Donnell, M., Moroianu, J., and Garcea, R. L., Possible role for 
cellular karyopherins in regulating polyomavirus and papillomavirus capsid 
assembly. J Virol, 2008. 82(20): p. 9848-57. 
70. Nelson, L.M., Rose, R.C., and Moroianu, J., Nuclear import strategies of 
high risk HPV16 L1 major capsid protein. J Biol Chem, 2002. 277(26): p. 
23958-64. 
71. Mamoor, S., Onder, Z., Karanam, B., Kwak, K., Bordeaux, J., Crosby, L., 
Roden, R. B., and Moroianu, J., The high risk HPV16 L2 minor capsid 
protein has multiple transport signals that mediate its nucleocytoplasmic 
traffic. Virology, 2012. 422(2): p. 413-24. 
72. Yu, J. H., Lin, B. Y., Deng, W., Broker, T. R., and Chow, L. T., Mitogen-
activated protein kinases activate the nuclear localization sequence of 
human papillomavirus type 11 E1 DNA helicase to promote efficient 
nuclear import. J Virol, 2007. 81(10): p. 5066-78. 
73. Fradet-Turcotte, A., Moody, C., Laimins, L. A., and Archambault, J., 
Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 
phosphorylation and required for viral genome maintenance. J Virol, 2010. 
84(22): p. 11747-60. 
74. Bian, X. L., Rosas-Acosta, G., Wu, Y. C., and Wilson, V. G., Nuclear 
import of bovine papillomavirus type 1 E1 protein is mediated by multiple 
alpha importins and is negatively regulated by phosphorylation near a 
nuclear localization signal. J Virol, 2007. 81(6): p. 2899-908. 
75. Klucevsek, K., Wertz, M., Lucchi, J., Leszczynski, A., and Moroianu, J., 
Characterization of the nuclear localization signal of high risk HPV16 E2 
protein. Virology, 2007. 360(1): p. 191-8. 
76. Skiadopoulos, M.H. and McBride, A.A., The bovine papillomavirus type 1 
E2 transactivator and repressor proteins use different nuclear localization 
signals. J Virol, 1996. 70(2): p. 1117-24. 
 110
77. Zou, N., Lin, B. Y., Duan, F., Lee, K. Y., Jin, G., Guan, R., Yao, G., 
Lefkowitz, E. J., Broker, T. R., and Chow, L. T., The hinge of the human 
papillomavirus type 11 E2 protein contains major determinants for nuclear 
localization and nuclear matrix association. J Virol, 2000. 74(8): p. 3761-
70. 
78. Blachon, S., Bellanger, S., Demeret, C., and Thierry, F., Nucleo-
cytoplasmic shuttling of high risk human Papillomavirus E2 proteins 
induces apoptosis. J Biol Chem, 2005. 280(43): p. 36088-98. 
79. Bian, X.L. and Wilson, V.G., Common importin alpha specificity for 
papillomavirus E2 proteins. Virus Res, 2010. 150(1-2): p. 135-7. 
80. Krawczyk, E., Hanover, J. A., Schlegel, R., and Suprynowicz, F. A., 
Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein. 
Biochem Biophys Res Commun, 2008. 371(4): p. 684-8. 
81. Le Roux, L.G. and Moroianu, J., Nuclear entry of high-risk human 
papillomavirus type 16 E6 oncoprotein occurs via several pathways. J 
Virol, 2003. 77(4): p. 2330-7. 
82. Tao, M., Kruhlak, M., Xia, S., Androphy, E., and Zheng, Z. M., Signals that 
dictate nuclear localization of human papillomavirus type 16 oncoprotein 
E6 in living cells. J Virol, 2003. 77(24): p. 13232-47. 
83. Angeline, M., Merle, E., and Moroianu, J., The E7 oncoprotein of high-risk 
human papillomavirus type 16 enters the nucleus via a nonclassical Ran-
dependent pathway. Virology, 2003. 317(1): p. 13-23. 
84. Knapp, A. A., McManus, P. M., Bockstall, K., and Moroianu, J., 
Identification of the nuclear localization and export signals of high risk 
HPV16 E7 oncoprotein. Virology, 2009. 383(1): p. 60-8. 
85. Eberhard, J., Onder, Z., and Moroianu, J., Nuclear import of high risk 
HPV16 E7 oncoprotein is mediated by its zinc-binding domain via 
hydrophobic interactions with Nup62. Virology, 2013. 446(1-2): p. 334-45. 
86. McKee, C. H., Onder, Z., Ashok, A., Cardoso, R., and Moroianu, J., 
Characterization of the transport signals that mediate the 
nucleocytoplasmic traffic of low risk HPV11 E7. Virology, 2013. 443(1): p. 
113-22. 
87. Piccioli, Z., McKee, C. H., Leszczynski, A., Onder, Z., Hannah, E. C., 
Mamoor, S., Crosby, L., and Moroianu, J., The nuclear localization of low 
risk HPV11 E7 protein mediated by its zinc binding domain is independent 
of nuclear import receptors. Virology, 2010. 407(1): p. 100-9. 
88. Onder, Z. and Moroianu, J., Nuclear import of cutaneous beta genus 
HPV8 E7 oncoprotein is mediated by hydrophobic interactions between its 
zinc-binding domain and FG nucleoporins. Virology, 2014. 449: p. 150-62. 
89. Esmaeili, M.J. and Mohabatkar, H., Computational prediction of nuclear 
localization signals and structural characteristics of 91 types of HPV E6 
proteins. Asian Pac J Cancer Prev, 2008. 9(4): p. 631-6. 
90. Antson, A. A., Burns, J. E., Moroz, O. V., Scott, D. J., Sanders, C. M., 
Bronstein, I. B., Dodson, G. G., Wilson, K. S., and Maitland, N. J., 
Structure of the intact transactivation domain of the human papillomavirus 
E2 protein. Nature, 2000. 403(6771): p. 805-9. 
 111
91. Hegde, R.S. and Androphy, E.J., Crystal structure of the E2 DNA-binding 
domain from human papillomavirus type 16: implications for its DNA 
binding-site selection mechanism. J Mol Biol, 1998. 284(5): p. 1479-89. 
92. Hegde, R. S., Grossman, S. R., Laimins, L. A., and Sigler, P. B., Crystal 
structure at 1.7 A of the bovine papillomavirus-1 E2 DNA-binding domain 
bound to its DNA target. Nature, 1992. 359(6395): p. 505-12. 
93. Kim, S. S., Tam, J. K., Wang, A. F., and Hegde, R. S., The structural basis 
of DNA target discrimination by papillomavirus E2 proteins. J Biol Chem, 
2000. 275(40): p. 31245-54. 
94. Harris, S.F. and Botchan, M.R., Crystal structure of the human 
papillomavirus type 18 E2 activation domain. Science, 1999. 284(5420): p. 
1673-7. 
95. Nadra, A. D., Eliseo, T., Mok, Y. K., Almeida, C. L., Bycroft, M., Paci, M., 
de Prat-Gay, G., and Cicero, D. O., Solution structure of the HPV-16 E2 
DNA binding domain, a transcriptional regulator with a dimeric beta-barrel 
fold. J Biomol NMR, 2004. 30(2): p. 211-4. 
96. Dell, G., Wilkinson, K. W., Tranter, R., Parish, J., Leo Brady, R., and 
Gaston, K., Comparison of the structure and DNA-binding properties of 
the E2 proteins from an oncogenic and a non-oncogenic human 
papillomavirus. J Mol Biol, 2003. 334(5): p. 979-91. 
97. Hernandez-Ramon, E. E., Burns, J. E., Zhang, W., Walker, H. F., Allen, S., 
Antson, A. A., and Maitland, N. J., Dimerization of the human 
papillomavirus type 16 E2 N terminus results in DNA looping within the 
upstream regulatory region. J Virol, 2008. 82(10): p. 4853-61. 
98. Gagnon, D., Senechal, H., D'Abramo, C. M., Alvarez, J., McBride, A. A., 
and Archambault, J., Genetic analysis of the E2 transactivation domain 
dimerization interface from bovine papillomavirus type 1. Virology, 2013. 
439(2): p. 132-9. 
99. McBride, A.A., Byrne, J.C., and Howley, P.M., E2 polypeptides encoded 
by bovine papillomavirus type 1 form dimers through the common 
carboxyl-terminal domain: transactivation is mediated by the conserved 
amino-terminal domain. Proc Natl Acad Sci U S A, 1989. 86(2): p. 510-4. 
100. Prakash, S. S., Grossman, S. R., Pepinsky, R. B., Laimins, L. A., and 
Androphy, E. J., Amino acids necessary for DNA contact and dimerization 
imply novel motifs in the papillomavirus E2 trans-activator. Genes Dev, 
1992. 6(1): p. 105-16. 
101. Corina, K., Grossman, S. R., Barsoum, J., Prakash, S. S., Androphy, E. J., 
and Pepinsky, R. B., The tryptophan bridge is a critical feature of the 
papillomavirus E2 DNA binding domain. Virology, 1993. 197(1): p. 391-6. 
102. Mok, Y. K., de Prat Gay, G., Butler, P. J., and Bycroft, M., Equilibrium 
dissociation and unfolding of the dimeric human papillomavirus strain-16 
E2 DNA-binding domain. Protein Sci, 1996. 5(2): p. 310-9. 
103. Winokur, P.L. and McBride, A.A., Separation of the transcriptional 
activation and replication functions of the bovine papillomavirus-1 E2 
protein. EMBO J, 1992. 11(11): p. 4111-8. 
 112
104. Dellarole, M., Sanchez, I. E., Freire, E., and de Prat-Gay, G., Increased 
stability and DNA site discrimination of "single chain" variants of the 
dimeric beta-barrel DNA binding domain of the human papillomavirus E2 
transcriptional regulator. Biochemistry, 2007. 46(43): p. 12441-50. 
105. Sakai, H., Yasugi, T., Benson, J. D., Dowhanick, J. J., and Howley, P. M., 
Targeted mutagenesis of the human papillomavirus type 16 E2 
transactivation domain reveals separable transcriptional activation and 
DNA replication functions. J Virol, 1996. 70(3): p. 1602-11. 
106. Dowhanick, J.J., McBride, A.A., and Howley, P.M., Suppression of cellular 
proliferation by the papillomavirus E2 protein. J Virol, 1995. 69(12): p. 
7791-9. 
107. Nishimura, A., Ono, T., Ishimoto, A., Dowhanick, J. J., Frizzell, M. A., 
Howley, P. M., and Sakai, H., Mechanisms of human papillomavirus E2-
mediated repression of viral oncogene expression and cervical cancer cell 
growth inhibition. J Virol, 2000. 74(8): p. 3752-60. 
108. Gammoh, N., Grm, H. S., Massimi, P., and Banks, L., Regulation of 
human papillomavirus type 16 E7 activity through direct protein interaction 
with the E2 transcriptional activator. J Virol, 2006. 80(4): p. 1787-97. 
109. Ferber, M. J., Montoya, D. P., Yu, C., Aderca, I., McGee, A., Thorland, E. 
C., Nagorney, D. M., Gostout, B. S., Burgart, L. J., Boix, L., Bruix, J., 
McMahon, B. J., Cheung, T. H., Chung, T. K., Wong, Y. F., Smith, D. I., 
and Roberts, L. R., Integrations of the hepatitis B virus (HBV) and human 
papillomavirus (HPV) into the human telomerase reverse transcriptase 
(hTERT) gene in liver and cervical cancers. Oncogene, 2003. 22(24): p. 
3813-20. 
110. Ferber, M. J., Thorland, E. C., Brink, A. A., Rapp, A. K., Phillips, L. A., 
McGovern, R., Gostout, B. S., Cheung, T. H., Chung, T. K., Fu, W. Y., and 
Smith, D. I., Preferential integration of human papillomavirus type 18 near 
the c-myc locus in cervical carcinoma. Oncogene, 2003. 22(46): p. 7233-
42. 
111. Hibma, M. H., Raj, K., Ely, S. J., Stanley, M., and Crawford, L., The 
interaction between human papillomavirus type 16 E1 and E2 proteins is 
blocked by an antibody to the N-terminal region of E2. Eur J Biochem, 
1995. 229(2): p. 517-25. 
112. Stubenrauch, F., Straub, E., Fertey, J., and Iftner, T., The E8 repression 
domain can replace the E2 transactivation domain for growth inhibition of 
HeLa cells by papillomavirus E2 proteins. Int J Cancer, 2007. 121(10): p. 
2284-92. 
113. Abbate, E.A., Voitenleitner, C., and Botchan, M.R., Structure of the 
papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates 
HPV chromosomal association. Mol Cell, 2006. 24(6): p. 877-89. 
114. McPhillips, M. G., Oliveira, J. G., Spindler, J. E., Mitra, R., and McBride, A. 
A., Brd4 is required for e2-mediated transcriptional activation but not 
genome partitioning of all papillomaviruses. J Virol, 2006. 80(19): p. 9530-
43. 
 113
115. Cardenas-Mora, J., Spindler, J. E., Jang, M. K., and McBride, A. A., 
Dimerization of the papillomavirus E2 protein is required for efficient 
mitotic chromosome association and Brd4 binding. J Virol, 2008. 82(15): p. 
7298-305. 
116. Oliveira, J.G., Colf, L.A., and McBride, A.A., Variations in the association 
of papillomavirus E2 proteins with mitotic chromosomes. Proc Natl Acad 
Sci U S A, 2006. 103(4): p. 1047-52. 
117. Brown, C., Kowalczyk, A. M., Taylor, E. R., Morgan, I. M., and Gaston, K., 
P53 represses human papillomavirus type 16 DNA replication via the viral 
E2 protein. Virol J, 2008. 5: p. 5. 
118. Wallace, N.A. and Galloway, D.A., Manipulation of cellular DNA damage 
repair machinery facilitates propagation of human papillomaviruses. 
Semin Cancer Biol, 2014. doi: 10.1016: [Epub ahead of print] 
119. Wells, S. I., Francis, D. A., Karpova, A. Y., Dowhanick, J. J., Benson, J. D., 
and Howley, P. M., Papillomavirus E2 induces senescence in HPV-
positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J, 2000. 
19(21): p. 5762-71. 
120. Bellanger, S., Demeret, C., Goyat, S., and Thierry, F., Stability of the 
human papillomavirus type 18 E2 protein is regulated by a proteasome 
degradation pathway through its amino-terminal transactivation domain. J 
Virol, 2001. 75(16): p. 7244-51. 
121. Bellanger, S., Tan, C. L., Nei, W., He, P. P., and Thierry, F., The human 
papillomavirus type 18 E2 protein is a cell cycle-dependent target of the 
SCFSkp2 ubiquitin ligase. J Virol, 2010. 84(1): p. 437-44. 
122. Johansson, C., Graham, S. V., Dornan, E. S., and Morgan, I. M., The 
human papillomavirus 16 E2 protein is stabilised in S phase. Virology, 
2009. 394(2): p. 194-9. 
123. Penrose, K.J. and McBride, A.A., Proteasome-mediated degradation of 
the papillomavirus E2-TA protein is regulated by phosphorylation and can 
modulate viral genome copy number. J Virol, 2000. 74(13): p. 6031-8. 
124. Penrose, K. J., Garcia-Alai, M., de Prat-Gay, G., and McBride, A. A., 
Casein Kinase II phosphorylation-induced conformational switch triggers 
degradation of the papillomavirus E2 protein. J Biol Chem, 2004. 279(21): 
p. 22430-9. 
125. Chang, S. W., Tsao, Y. P., Lin, C. Y., and Chen, S. L., NRIP, a novel 
calmodulin binding protein, activates calcineurin to dephosphorylate 
human papillomavirus E2 protein. J Virol, 2011. 85(13): p. 6750-63. 
126. Bellanger, S., Blachon, S., Mechali, F., Bonne-Andrea, C., and Thierry, F., 
High-risk but not low-risk HPV E2 proteins bind to the APC activators 
Cdh1 and Cdc20 and cause genomic instability. Cell Cycle, 2005. 4(11): p. 
1608-15. 
127. Bellanger, S., Tan, C. L., Xue, Y. Z., Teissier, S., and Thierry, F., Tumor 
suppressor or oncogene? A critical role of the human papillomavirus 
(HPV) E2 protein in cervical cancer progression. Am J Cancer Res, 2011. 
1(3): p. 373-389. 
 114
128. Xue, Y., Bellanger, S., Zhang, W., Lim, D., Low, J., Lunny, D., and Thierry, 
F., HPV16 E2 is an immediate early marker of viral infection, preceding E7 
expression in precursor structures of cervical carcinoma. Cancer Res, 
2010. 70(13): p. 5316-25. 
129. Muller, M., Jacob, Y., Jones, L., Weiss, A., Brino, L., Chantier, T., Lotteau, 
V., Favre, M., and Demeret, C., Large scale genotype comparison of 
human papillomavirus E2-host interaction networks provides new insights 
for e2 molecular functions. PLoS Pathog, 2012. 8(6): p. e1002761. 
130. Muller, M. and Demeret, C., The HPV E2-Host Protein-Protein 
Interactions: A Complex Hijacking of the Cellular Network. Open Virol J, 
2012. 6: p. 173-89. 
131. Olejnik-Schmidt, A. K., Schmidt, M. T., Kedzia, W., and Gozdzicka-
Jozefiak, A., Search for cellular partners of human papillomavirus type 16 
E2 protein. Arch Virol, 2008. 153(5): p. 983-90. 
132. Ramirez-Salazar, E., Centeno, F., Nieto, K., Valencia-Hernandez, A., 
Salcedo, M., and Garrido, E., HPV16 E2 could act as down-regulator in 
cellular genes implicated in apoptosis, proliferation and cell differentiation. 
Virol J, 2011. 8: p. 247. 
133. Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. 
C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., Knott, C., Lin, 
F., Boyer, J. D., Draghia-Akli, R., White, C. J., Kim, J. J., Weiner, D. B., 
and Sardesai, N. Y., Immunotherapy against HPV16/18 generates potent 
TH1 and cytotoxic cellular immune responses. Sci Transl Med, 2012. 
4(155): p. 155ra138. 
134. Sethi, N. and Palefsky, J., Treatment of human papillomavirus (HPV) type 
16-infected cells using herpes simplex virus type 1 thymidine kinase-
mediated gene therapy transcriptionally regulated by the HPV E2 protein. 
Hum Gene Ther, 2003. 14(1): p. 45-57. 
135. Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., 
Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., and Yoshinouchi, M., New 
highly potent and specific E6 and E7 siRNAs for treatment of HPV16 
positive cervical cancer. Cancer Gene Ther, 2008. 15(3): p. 140-53. 
136. D'Abramo, C.M. and Archambault, J., Small molecule inhibitors of human 
papillomavirus protein - protein interactions. Open Virol J, 2011. 5: p. 80-
95. 
137. Butterfield-Gerson, K. L., Scheifele, L. Z., Ryan, E. P., Hopper, A. K., and 
Parent, L. J., Importin-beta family members mediate alpharetrovirus gag 
nuclear entry via interactions with matrix and nucleocapsid. J Virol, 2006. 
80(4): p. 1798-806. 
138. Gudleski, N., Flanagan, J. M., Ryan, E. P., Bewley, M. C., and Parent, L. 
J., Directionality of nucleocytoplasmic transport of the retroviral gag 
protein depends on sequential binding of karyopherins and viral RNA. 
Proc Natl Acad Sci U S A, 2010. 107(20): p. 9358-63. 
139. Parent, L.J., New insights into the nuclear localization of retroviral Gag 
proteins. Nucleus, 2011. 2(2): p. 92-7. 
 115
140. Plafker, S.M. and Macara, I.G., Importin-11, a nuclear import receptor for 
the ubiquitin-conjugating enzyme, UbcM2. EMBO J, 2000. 19(20): p. 
5502-13. 
141. Spitzer, M., Wildenhain, J., Rappsilber, J., and Tyers, M. B., BoxPlotR: a 
web tool for generation of box plots. Nat Methods, 2014. 11(2): p. 121-2. 
142. Hoffman, C.S. and Winston, F., A ten-minute DNA preparation from yeast 
efficiently releases autonomous plasmids for transformation of Escherichia 
coli. Gene, 1987. 57(2-3): p. 267-72. 
143. Hoffman, C.S. and Winston, F., Isolation and characterization of mutants 
constitutive for expression of the fbp1 gene of Schizosaccharomyces 
pombe. Genetics, 1990. 124(4): p. 807-16. 
144. Fehrmann, F. and Laimins, L.A., Human papillomaviruses: targeting 
differentiating epithelial cells for malignant transformation. Oncogene, 
2003. 22(33): p. 5201-7.  
145. Lee, B. J., Cansizoglu, A. E., Suel, K. E., Louis, T. H., Zhang, Z., and 
Chook, Y. M., Rules for nuclear localization sequence recognition by 
karyopherin β2. Cell, 2006. 126: p. 543-558 
146. Plafker, S. M., and Macara, I. G., Ribosomal protein L12 uses a distinct 
nuclear import pathway mediated by importin 11. Mol Cell Biol, 2002. 22: p. 
1266-1275 
147. Ivey, F. D., Taglia, F. X., Yang, F., Lander, M. M., Kelly, D. A., and 
Hoffman, C. S., Activated alleles of the Schizosaccharomyces pombe 
gpa2+ Gα gene identify residues involved in GDP-GTP exchange. 
Eukaryot Cell, 2010. 9: p. 626-633 
148. Sheng, Y., Hong, J. H., Doherty, R., Srikumar, T., Shloush, J., Avvakumov, 
G. V., Walker, J. R., Xue, S., Neculai, D., Wan, J. W., Kim, S. K., 
Arrowsmith, C. H., Raught, B., and Dhe-Paganon, S., A human ubiquitin 
conjugating enzyme (E2)-HECT E3 ligase structure-function screen. Mol 
Cell Proteomics, 2012. 11: p. 329-341 
149. van Wijk, S. J., and Timmers, H. T., The family of ubiquitin-conjugating 
enzymes (E2s): deciding between life and death of proteins. FASEB J, 
2010. 24: p. 981-993 
150. Oh, K. J., Kalinina, A., and Bagchi, S., Destabilization of Rb by human 
papillomavirus E7 is cell cycle dependent: E2-25K is involved in the 
proteolysis. Virology, 2009. 396: p. 118-124 
151. Pulliam, K. F., Fasken, M. B., McLane, L. M., Pulliam, J. V., and Corbett, A. 
H., The classical nuclear localization signal receptor, importin-alpha, is 
required for efficient transition through the G1/S stage of the cell cycle in 
Saccharomyces cerevisiae. Genetics, 2009. 181: p. 105-118 
152. Jans, D. A., Briggs, L. J., Gustin, S. E., Jans, P., Ford, S., and Young, I. 
G., The cytokine interleukin-5 (IL-5) effects cotransport of its receptor 
subunits to the nucleus in vitro. FEBS Lett, 1997. 410: p. 368-372 
153. Xia, Y. P., Yeh, C. T., Ou, J. H., and Lai, M. M., Characterization of 
nuclear targeting signal of hepatitis delta antigen: nuclear transport as a 
protein complex. J Virol, 1992. 66: p. 914-921 
 116
154. Shiota, C., Coffey, J., Grimsby, J., Grippo, J. F., and Magnuson, M. A., 
Nuclear import of hepatic glucokinase depends upon glucokinase 
regulatory protein, whereas export is due to a nuclear export signal 
sequence in glucokinase. J Biol Chem, 1999. 274: p. 37125-37130 
155. Sachdev, S., Hoffmann, A., and Hannink, M., Nuclear localization of IκBα 
is mediated by the second ankyrin repeat: the IκBα ankyrin repeats define 
a novel class of cis-acting nuclear import sequences. Mol Cell Biol, 1998. 
18: p. 2524-2534 
156. Chen, M. H., Ben-Efraim, I., Mitrousis, G., Walker-Kopp, N., Sims, P. J., 
and Cingolani, G., Phospholipid scramblase 1 contains a nonclassical 
nuclear localization signal with unique binding site in importin α. J Biol 
Chem, 2005. 280: p. 10599-10606 
157. Plafker, S. M., Plafker, K. S., Weissman, A. M., and Macara, I. G., 
Ubiquitin charging of human class III ubiquitin-conjugating enzymes 
triggers their nuclear import. J Cell Biol, 2004. 167: p. 649-659 
158. Jakel, S., Mingot, J. M., Schwarzmaier, P., Hartmann, E., and Gorlich, D., 
Importins fulfil a dual function as nuclear import receptors and cytoplasmic 
chaperones for exposed basic domains. EMBO J, 2002. 21: p. 377-386 
159. Aparicio, F., Sanchez-Navarro, J. A., and Pallas, V., In vitro and in vivo 
mapping of the Prunus necrotic ringspot virus coat protein C-terminal 
dimerization domain by bimolecular fluorescence complementation. J Gen 
Virol, 2006.  87: p. 1745-1750 
160. Choi, G., Lee, S. W., Jung, K. C., and Choi, E. Y., Detection of homodimer 
formation of CD99 through extracelluar domain using bimolecular 
fluorescence complementation analysis. Exp Mol Med, 2007. 39: p. 746-
755 
 
 
 
 
 
